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ABSTRACT 
Epilepsy is considered to be the neurological disease that gives the largest burden of disease 
in children. It is a heterogeneous disease with very diverse consequences in the lives of the 
patient. Comorbidities with other neurological, as well as developmental, and psychiatric, 
diseases are common.   
The aim of this thesis was to describe the incidence of epileptic seizures in children and 
adults, the prevalence of neurodevelopmental comorbidities and cerebral palsy (CP) in 
children with seizures, and the implication of these comorbidities on the seizure prognosis in 
children. 
The thesis was based on data from the Stockholm Incidence Registry of Epilepsy (SIRE). 
Medical records of all inhabitants of a designated area in northern Stockholm, seeking 
medical assistance for an unprovoked seizure between September 1st 2001 and December 
31st 2006 were screened. Those who were diagnosed with an epileptic seizure for the first 
time (index seizure) during that timeframe were included in the Stockholm Incidence 
Registry of Epilepsy (SIRE). Medical records from before, and up until six months after, the 
index seizure were assessed regarding seizure type, epilepsy type and aetiology. The 
comorbidities developmental delay, speech/language and learning diﬃculties, intellectual 
disability, CP, autism spectrum disorder (ASD), attention deficit hyperactivity disorder 
(ADHD) and unspeciﬁed psychiatric disorders were given special attention. The medical 
records of the children in SIRE were also assessed two years after the index seizure for 
information regarding the neurodevelopmental comorbidities and CP, treatment with 
antiepileptic drugs (AEDs) and seizure remission. SIRE was also linked to the Swedish 
Prescribed Drug Registry (SPDR) for the period 2005–2014, where information of the use of 
AEDs, neuroleptics, antidepressants and medication for ADHD was retrieved. 
Study I included all patients (of all ages, 56% men) included in SIRE between Sept 1st 2001 
and Aug 31st 2004 (N=1015). The incidence of a first unprovoked seizure was 35/100,000 
person years (95% CI: 33.3–37.6). Seizure classification was possible in 72%, with 
generalized seizure debut only identified among those younger than 50 years old. A presumed 
aetiology was identified in 28% of the children (0–15 years old), in 37% of those 15 to 69 
years, and in 64% of those over 70 years old. Stroke (11%) and brain tumours (9%) were the 
most common causes (primarily in adults). Neurological deficits from births were identified 
in 10% of the patients. The methodology of SIRE seemed effective regarding identification of 
seizure patients. 
Study II included all children (28 days up to 19 years old, 56% boys) included in SIRE 
between Sept 1st 2001 and Dec 31st 2006 (n=766). The seizure incidence was 67/100,000 
person years overall and highest for those younger than one-year-old (204/100,000). 
Neurodevelopmental comorbidity or CP was found in 32% of the children, and 11% had 
more than one of the defined comorbidities. 
Study III was based on a 2-year follow-up of children included in Study II (n=750 with 
available records). Neurodevelopmental comorbidity or CP was found in 35% (95% CI:32–
38%) of the children. Remission from seizures month 13 to 24 after the index seizure, or start 
of treatment with AEDs, was achieved by 69% of all the children, but those with a 
neurodevelopmental comorbidity or CP still had seizures almost three times as often as those 
without a comorbidity (OR: 2.87, 95% CI:2.07–3.99). 
Study IV was also based on the children in Study II, with a few new inclusions due to late 
access to medical journals (n=769). Eight years after the index seizure, 31% of all the 
children were still dispensed AEDs, four times more often to children with 
neurodevelopmental comorbidity or CP compared to those without (OR: 4.0 95% CI: 2.9–
5.6). Neuroleptics, antidepressants and drugs for ADHD were dispensed to between 1-5% of 
the children in SIRE, this was 2–10 times more often than what was reported in the general 
population at the time. 
In conclusion, neurodevelopmental comorbidities and CP were common among children with 
epileptic seizures and were present already at the time of onset of seizures. This indicating 
that these conditions may have a common innate cause, rather than epilepsy per se causing 
the neurodevelopmental deficiencies. Children with comorbidities were less likely to achieve 
seizures remission and also more likely to receive treatment with neuroleptics, 
antidepressants and medication for ADHD. The clinical implication of these findings is that 
children with a first unprovoked seizure should be assessed for neurodevelopmental 
comorbidities and CP. This since these diagnoses are more prevalent in this group and 
deserves attention, and since children with these comorbidities have a worse prognosis and 
may benefit from more careful monitoring regarding their seizures. 
 
 
 
 
 
 
 
 
 
  
SVENSK SAMMANFATTNING 
Cirka var tionde person i världen kommer någon gång att få ett epilepsianfall, och ungefär en 
tredjedel av dem kommer att utveckla epilepsi. Epilepsi är vanligast under de första 
levnadsåren och hos äldre. Samsjuklighet med andra neurologiska och neuropsykiatriska 
sjukdomar är vanligt. 
Avhandlingen behandlar förekomsten av nyinsjuknande i epilepsianfall hos barn och vuxna i 
Norra Stockholms län och hur eventuell samsjuklighet hos dessa barn påverkar anfallsfrihet, 
samt framtida användande av neuroleptika, antidepressiva och läkemedel mot ADHD. 
Avhandlingen baseras på data från Stockholm Incidence Registry of Epilepsy (SIRE). 
Patienter, utan tidigare känd anfallssjukdom, som sökte vård för ett anfall identifierades via 
EEG-remisser och rapporter från kliniker i upptagningsområdet, mellan 1 september 2001 
och 31 december 2006. Indexanfallet definierades som det anfall som gjorde att patienten 
sökte vård. Sex månader efter indexanfallet samlades relevanta journalhandlingar in för 
baslinjesammanställningen. Om det rapporterade anfallet bedömdes som ett oprovocerat, 
förstagångsanfall inkluderades patienten i SIRE. Journalinformation avseende anfallstyp, 
epilepsityp och etiologi inhämtades. Samsjuklighet som speciellt granskades var: 
psykomotorisk utvecklingsförsening, tal-, språk-, och inlärningssvårigheter, ADHD, 
autismspektrumsjukdomar, cerebral pares, intellektuell funktionsnedsättning och annan 
psykiatrisk sjukdom. För barnen som inkluderats i SIRE gjordes även en journalgranskning 
två år efter index. Då inhämtades också information om eventuell epilepsibehandling och 
anfallsfrekvens. SIRE sammanfogades med information från Läkemedelsregistret kring uttag 
av antiepileptika (AED), antidepressiva, neuroleptika och läkemedel mot ADHD.  
Studie I inkluderade alla patienter (alla åldrar, 56 % män) som inkluderats i SIRE mellan 1 
september 2001 och 31 december 2004 (N=1015). Incidens för ett första oprovocerat anfall 
var 35/100 000 personår. Anfallsklassifikation kunde göras för 72 % av patienterna, med 
generaliserad anfallsdebut bara identifierad bland patienter yngre än 50 år. En trolig etiologi 
kunde fastställas hos 28 % av barnen (0–15 år), hos 37 % av patienterna mellan 15 och 69 år, 
och 64 % av de som var äldre än 70 år. De vanligaste etiologierna var stroke (11 %) och 
hjärntumörer (9 %), bägge framför allt diagnosticerade hos vuxna. Medfödda neurologiska 
avvikelser identifierades hos 10 % av patienterna. Metoden för att identifiera patienter med 
anfall föreföll robust. 
Studie II inkluderade alla barn (28 dagar – 19 år, 56 % pojkar) som inkluderats i SIRE mellan 
1 september 2001 och 31 december 2006 (n=766). Anfallsincidensen var 67/100 000 
personår, högst för de yngre än ett år (204/100 000). Utvecklingsneurologisk samsjuklighet 
och/eller CP konstaterades hos 32 %, och 11 % av barnen hade mer än en av de definierade 
samsjukligheterna. 
Studie III var en 2-års uppföljning av barnen i Studie II (n=750, med kompletta 
journaluppgifter). Efter 24 månader konstaterades utvecklingsneurologisk samsjuklighet 
och/eller CP hos 35 % (95 % CI: 32– 38 %). De med samsjuklighet hade högre risk för 
fortsatta anfall månad 13–24 efter indexanfallet, eller insättande av antiepileptika. 
Anfallsfrihet uppnåddes under denna period hos 69 % av alla barnen, men nästan tre gånger 
så många av de med utvecklingsneurologisk samsjuklighet eller CP fortsatte att ha anfall, 
jämfört med de utan samsjuklighet (OR: 2.87, 95 % CI: 2.07–3.99).  
I Studie IV gjordes en sammanslagning av uppgifterna för barnen i Studie II (n=769, på grund 
av några sena journalkompletteringar) med Läkemedelsregistret. Åtta år efter indexanfallet 
hämtade 31 % av alla barnen ut antiepileptika på apoteket, läkemedelsuttag var fyra gånger så 
vanligt hos barn med utvecklingsneurologisk samsjuklighet och/eller CP än hos dem utan 
(OR: 4.0, 95 %, CI: 2.9–5.6). Totalt hämtade 1–5 % av barnen ut läkemedel mot ADHD, 
antidepressiva eller neuroleptika, vilket var 2–10 gånger så ofta i relation till det rapporterade 
uttaget av dessa läkemedel hos den totala barnpopulationen i Stockholm under denna 
tidsperiod.  
Studierna i avhandlingen visade sammanfattningsvis på en incidens för ett förstagångsanfall 
hos barn i enlighet med tidigare internationella studier och att de definierade 
samsjukligheterna fanns redan vid anfallsdebut. Detta talar emot att epilepsin skulle orsaka 
utvecklingsavvikelsen, utan i stället för att det finns en gemensam, bakomliggande orsak till 
sjukdomarna. Barn med samsjuklighet hade lägre sannolikhet att bli anfallsfria under månad 
13–24 efter indexanfallet, och fler av dem behandlades med antiepileptika, antidepressiva, 
neuroleptika och läkemedel mot ADHD åtta år efter indexanfallet, jämfört med barnen utan 
samsjuklighet. Barn med ett förstagångsanfall bör alltså bedömas avseende neurologiska 
utvecklingsavvikelser och neuropsykiatriska tillstånd. Detta då diagnoserna förekommer 
oftare hos barn med epilepsi jämfört med barn inom normalpopulationen, och då denna 
samsjuklighet påverkar epilepsiprognosen. 
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1 INTRODUCTION 
 
‘I do not believe that the Sacred Disease is any more divine than any other disease but, on the 
contrary, has specific characteristics and a definite cause…The brain is the seat of this 
disease, as it is of other very violent diseases’. 
- Hippocrates, ‘On the Sacred Disease’ (400 BC). 
 
In spite of Hippocrates’ insightful description of this ancient disorder, the history of epilepsy 
has been described as ‘4000 years of ignorance, superstition and stigma, followed by 100 
years of knowledge, superstition and stigma’ (Kale, 1997). Among neurological disorders 
(excluding stroke) epilepsy is considered number three regarding burden of disease 
worldwide in all ages (2016) and number one in children and young adults (2017). Epilepsy 
affects both sexes, all ages, all races and all socioeconomic groups, although epilepsy is more 
common among adults in low socioeconomic groups, where risk factors of epilepsy are also 
more common (Beghi and Hesdorffer, 2014; Hesdorffer et al., 2005). Even though almost ten 
percent of a population will experience a seizure during their lifetime, and more than a third 
of them will develop epilepsy (Gavvala and Schuele, 2016), there are still a lot of 
misconceptions in society about epilepsy. Epilepsy is a disease which comes with restrictions 
regarding driving and recommendations about career choice and leisure activities due to the 
unpredictable seizures, which contradict many of societies demand for self-fulfilment and 
planning of one’s future. In some cultures, the thought of the disease being a punishment for 
sins or bewitchment still exists (Walker and Pinikahana, 2009). These cultural burdens, 
together with the consequences of the actual seizures, treatments, and comorbidities, are some 
of the challenges for a person with epilepsy. 
Epidemiological studies are important to assess the burden of a disease, to find risk factors 
and causes, to identify prognostic considerations and to allocate appropriate health-care 
means. Epidemiology in epilepsy, is complicated since it is a heterogeneous disease with 
diverse consequences and comorbidities, and there is no single test to confirm the diagnosis. 
New knowledge has led to recently updated classifications regarding epilepsy, with the 
intention of making communication more precise and in that way facilitate progress both in 
clinical and research settings. 
The main focus of the thesis is on the incidence of epilepsy and the prevalence of 
neurodevelopmental disorders and CP in children with seizures, and the impact of these 
comorbidities on the prognosis of children afflicted with epileptic seizures. This knowledge 
can provide prognostic information to patients and be of use for preventive measures and 
treatment decisions. 
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2 BACKGROUND 
2.1 EPILEPSY 
More is known about epilepsy now than when it was called the Sacred Disease at the time of 
Hippocrates, but there is still more knowledge to find and knowledge to be shared. To 
facilitate the research, and to help with the distribution of knowledge regarding epilepsy, the 
international professional organisation, the International League Against Epilepsia (ILAE), 
has published definitions and classifications which have been updated from time to time 
based on emerging data.  
According to the definition, epilepsy requires at least one epileptic seizure. Epileptic seizures 
are due to excessive, abnormal or synchronous signalling, or depolarisation, in the brain cells. 
This cellular action results in a sudden and temporary change in the person, with involuntary 
movements or abnormal experiences such as shift of awareness, a sensory event or an 
autonomic phenomenon, observed by the patient or a witness (Fisher et al., 2017b; Fisher et 
al., 2005). Single unprovoked epileptic seizures, or a cluster of seizures appearing within 24 
hours, or an episode of status epilepticus are defined as one seizure (Commission, 1993). 
Epileptic seizures start in the cerebral cortex, and all kinds of damage to the cortex increase 
the risk of lowering the threshold for seizures and cause epilepsy. Acute events such as head 
trauma, stroke and acute metabolic disease can give rise to seizures. Since these provoking 
events are temporary and the risk of seizures is small without the specific event, these 
seizures are not defined as epileptic, but are called ‘acute symptomatic seizures’. However, 
some of these medical events can result in lasting injuries, and in that way be risk factors for 
a later (months-years) diagnosis of epilepsy. Reflex seizures, which are another kind of 
seizure, are also dependent on specific, transient circumstances (e.g. photo stimuli) they are 
included in epilepsy since this is an enduring susceptibility to seizures. There are seizure 
imitators, such as vasovagal syncope, hypnagogic jerks, panic attacks, movement disorders 
and daydreaming, why the clinician has to ask for a detailed description of the event. To 
conclude; epileptic seizures are unprovoked, they are transient with a start and a finish, they 
have a clinical manifestation, and originate from an abnormal, enhanced synchronicity in the 
cells of the cortex.   
Epilepsy is defined as a lasting elevated susceptibility to generate these unprovoked seizures. 
The definition now also includes the neurobiological, cognitive, psychological and social 
consequences/aspects of the disease. In a clinical setting, this means that epilepsy is, at least 
one unprovoked seizure and a high risk of recurrent unprovoked seizures within ten years, or 
two seizures more than 24 hours apart, or the make-up of an epilepsy syndrome or reflex 
epilepsy (Fisher et al., 2014). A high risk of recurrent seizures is considered to be at least 
60%, since that is the general risk of further seizures after two seizures. Some known risk 
factors for a second seizure are (without automatically qualifying the patient for a diagnosis 
of epilepsy); if the first seizure was nocturnal, if epileptiform activity was seen on the 
electroencephalogram (EEG), if the computer tomography (CT) or magnetic resonance 
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imaging (MRI) was abnormal or if the patient had had a previous brain injury or disease 
(Krumholz et al., 2015). The previous definition of epilepsy (which is used in many 
population-based studies of epilepsy epidemiology) was at least two unprovoked seizures 
more than 24 hours apart (Commission, 1993). This is still the default definition if 
information, or lack of information, about the seizure makes evaluation of the recurrence risk 
insecure.  
The first level of classification of an unprovoked epileptic seizure is to decide on the seizure 
type. Using the clinical symptoms and signs of the seizure (i.e. semiology) and looking for 
familiar patterns and sometimes with the help of EEG and brain imaging, seizures can be 
grouped into seizure types with a generalized, focal or unknown onset (Fisher et al., 2017a; 
Fisher et al., 2017b). The definitions of seizure types have also changed over time. The focus 
is now on whether brain networks limited to one hemisphere, or both, are involved in the 
seizure. Generalized seizures do not always include the entire cortex but they rapidly engage 
networks in both hemispheres. Generalized seizures are divided into motor or non-motor 
(absence) seizures, and then further into smaller entities such as tonic-clonic, myoclonic, 
epileptic spasms. Focal seizures, on the other hand, are initiated from one hemisphere. The 
seizures can be very localised, or spread across large parts of the cortex (Berg et al., 2010). A 
focal seizure can consequently show ‘bilateral activity’ in an EEG. Focal seizures can also be 
motor and non-motor seizures. If the patient is unresponsive during all, or a part of, the 
seizure it is labelled as ‘impaired awareness’. A focal seizure can also be ‘focal to bilateral 
tonic-clonic’ (earlier called; secondary generalized seizure). 
The next level of classification is the epilepsy type. Some epilepsies consist of multiple 
seizure types. The semiology of the seizures, together with the EEG findings provide the 
epilepsy type. The categories are focal, generalized, combined focal and generalized or 
unknown. When the EEG is normal (or inconclusive), additional seizure types or family 
history can give away the epilepsy type (i.e. generalized tonic-clonic seizures with a normal 
EEG in combination with myoclonic jerks, supports a generalized epilepsy). Patients with 
both generalized and focal seizures now belong to the category called ‘Combined 
Generalized and Focal Epilepsies’. When the information is insufficient to determine the 
epilepsy type as either focal or generalized the term ‘Unknown’ should be used (Scheffer et 
al., 2017).  
The third level of classification is the diagnosis of the epilepsy syndrome. Here characteristics 
from the seizure (such as seizure type and triggers), the examinations (EEG and imaging 
features), and the patient (age at onset and remission, comorbidities etc.) can be grouped into 
recognised syndrome. These may have associated aetiological, prognostic and treatment  
         
 
 
  5 
 
 
Figure 1. Classification of Epilepsy-tree, including the three levels of classification and aetiologies, by Eva 
Åndell Jason. The branches of the seizure types include the expanded version with generalized; motor/non-
motor, focal; aware/impaired awareness, motor/non-motor, focal to bilateral clonic, unknown; motor/non-motor, 
unclassified. The tree is filled with different leaves depending on the presence of comorbidities. 
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implications. There are many well-accepted syndromes, such as childhood absence epilepsy 
and West syndrome, but these classifications have not been officially approved by the ILAE 
(Scheffer et al., 2017).   
Parallel with the attempts to classify the seizure(s), epilepsy type and the epilepsy syndrome, 
there should be a search for the aetiology of the disease. An epilepsy syndrome can have 
more than one aetiology, and sometimes aetiology gives additional information regarding 
prognosis and treatment choices (Scheffer et al., 2017). The specific aetiology of epilepsy is 
often unknown, but the probable group of aetiology is more often possible to determine. The 
groupings ILAE currently recommends are: structural; genetic; infectious; immune; 
metabolic; and unknown (Scheffer et al., 2017). The idea is that the epilepsy results from a 
disorder in one of these groups, and that the core symptom of the disorder is seizures. A 
structural aetiology refers to when abnormalities on neuroimaging and electroclinical 
findings are the likely cause of the seizures. Even though it might be a genetic, traumatic or 
infectious basis to the structural abnormality, the epilepsy derives from the structural cause. 
The genetic field has evolved rapidly over the last decade. Most of the mutations are not 
known yet, but the genetic cause of the syndrome has been determined through twin and 
family studies (Sanchez-Carpintero Abad et al., 2007). A genetic aetiology in epilepsy is not 
always hereditary, since there are a lot of de novo mutations causing epilepsy. In some parts 
of the world the most common aetiology of epilepsy is an infection. This refers both to 
epilepsy as a late consequence of an earlier acute infection, a congenital infection and 
infections with structural correlates like tuberculosis, HIV and neurocysticercosis. Evidence 
of autoimmune-mediated central nervous system inflammation leading to epilepsy, such as 
anti-NMDA-receptor encephalitis, were recently identified, adding an immune group to the 
aetiologies. With better access to antibody testing and targeted immunotherapies this group 
will become increasingly important. Some metabolic epilepsies are acquired, but most have a 
genetic base. The definition in epilepsy refers to well-known metabolic defects with negative 
effects on the whole body. The size of the group unknown differs between clinical settings 
and countries, since the definition is that the cause is not yet known, and this is dependent on 
the access to specialists and medical equipment. 
At the time of the large revision of definitions, the ILAE also decided to replace the term 
‘benign’ with self-limiting or pharmacoresponsive to give a more precise and correct 
description of the situation for the patient.  
‘Malignant’ and ‘catastrophic’ are other terms that have been removed and instead the terms 
developmental and/or epileptic encephalopathy were introduced. This pertains to epilepsies 
where the epileptic activity significantly adds to the developmental and behavioural 
impairment, resulting in more disability than was expected from the beginning (Berg et al., 
2010). In epileptic encephalopathy the epileptic activity intervenes with a previously normal 
development, leading to cognitive, behavioural and psychiatric difficulties. If the epileptiform 
activity decreases, there is a possibility of improvement also of the developmental 
consequences. Developmental encephalopathy is when there is a developmental component 
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independent of the epileptic activity. The two can also be combined. There might also be 
other comorbidities. Outcome for this group is often poor even if the seizures stop and it is 
important also in this group to define the aetiology (primarily genetic) which might differ 
between patients with the same epilepsy (Scheffer et al., 2017).  
When someone is treated for epilepsy, or had a seizure less than five years ago, that person is 
often defined as someone with active epilepsy (Commission, 1993). Epilepsy is resolved first 
if a person past the relevant age of an epilepsy syndrome that is self-limited, or after ten years 
of seizure-freedom without seizure medication for the last 5 years (Fisher et al., 2014). A 
seizure diagnosis has a great impact on a person’s life, which is why a diagnosis should be 
given with great respect and knowledge, and always be re-evaluated once in a while, since 
there is no definite marker or test for the diagnosis. 
The classifications in the studies of this thesis were made with the prevailing ILAE 
classifications at the beginning of this PhD-project. Epilepsy was defined as two or more 
seizures (Commission, 1981). Seizure types were then named generalized, partial (now 
focal), multiple seizure types or unclassified. The aetiologies were divided into symptomatic, 
cryptogenic or idiopathic (Commission, 1989). Symptomatic epilepsies were caused by a 
known brain disorder, cryptogenic by a suspected but not identified cause and idiopathic was 
used for specific syndromes with a known or presumed genetic cause (Commission, 1993, 
1997).   
2.2 EPILEPSY – EPIDEMIOLOGY 
Epidemiology is the study of the distribution and determinants of a disease in a defined 
population. To be useful, data need to be comparable over time and across studies. This 
makes definitions of terminology of great importance. Epilepsy is a heterogeneous disease 
and its occurrence and consequences have been found to differ between countries. These 
discrepancies may in part be explained by methodological problems (i.e. diagnostic 
misclassifications, different populations, differences in definitions and difficulties in 
identification of patients) and socioeconomic factors (i.e. differences in etiological factors, 
premature mortality, stigma and treatment opportunities). To facilitate comparison between 
studies, guidelines for epidemiological studies in epilepsy have been written and later updated 
(Commission, 1993, 1997; Thurman et al., 2011). These give directions regarding preferred 
measurement indexes, definitions and methodological issues.  
Prevalence is the proportion of individuals with a defined disease at a given time (Rothman, 
2012). The time could be specific (point prevalence), a time span (period prevalence) or a full 
life (lifetime prevalence). Incidence rate is the number of new cases in a population divided 
by the total time at risk of that population. The incidence for a disease with a short duration 
(fast recovery or death) and one with long duration (‘chronic’) might be the same, but the 
prevalence will differ a lot between these two examples. Cumulative incidence is the new 
cases divided by the number of persons at risk at baseline in the same population during a 
defined period of time, i.e. the person’s risk of developing epilepsy by the time of a specific 
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age. In both prevalence and incidence studies of epilepsy, specified inclusion criteria are of 
great importance. For incidence studies of epilepsy, it is important to define whether 
inclusion criteria are the diagnosis of epilepsy or onset of seizures. Incidence-based studies 
are primarily used to assess possible risk factors and aetiologies, to study time trends and for 
prognostic investigations, while prevalence-based studies primarily are important when 
evaluating disease burden and estimating needs of health care (Thurman et al., 2011). Ratios 
between incidences and prevalence’s across different groups are often calculated to assess the 
association between different determinants and disease occurrence. Hazard ratio refers to the 
rate of an event (events/time unit) in one group divided by the rate of the event in the 
reference group. Odds ratios is the ratio between the odds of the event in the two groups 
(odds=probability of event(p)/probability of no event (1-p)). As with all statistics, relative 
measures have to be interpreted with caution, since the ratio will depend not only on the 
strength of association but also on the frequency of the disease in the referent population.  
The point prevalence of epilepsy in the world was in a meta-analysis (197 prevalence studies) 
estimated to be 6.38 per 1000 (95% CI: 5,57–7.30), a little lower in high-income countries 
and among younger children. The overall incidence of epilepsy in the same meta-analysis 
(48 incidence studies) was found to be 61 per 100,000 person years (95% CI: 51–74/100,000) 
(Fiest et al., 2017). This would translate to 70,000 persons in Sweden having epilepsy. Young 
children (particularly under 1 year old) and elderly (from 65 years of age) have the highest 
risk of being diagnosed with epilepsy (Aaberg et al., 2017a; Forsgren et al., 2005; Olafsson et 
al., 2005).  
The incidence of a first unprovoked epileptic seizure in children is 40–104/100,000  while 
0.3–0.6% of all children in Europe and North America have epilepsy at any given time point, 
the prevalence seems to be higher in other areas (highest in Latin America with 
7.5– 44.3/1000) (Aaberg et al., 2017a; Camfield and Camfield, 2015; Kim et al., 2016; 
Larsson and Eeg-Olofsson, 2006; Olafsson et al., 2005). Thus, every year at least 1000 
children and 3000 adults in Sweden are diagnosed with epilepsy. 
For an unbiased assessment of the incidence of unprovoked seizures and epilepsy in a 
population large prospective population-based studies are needed. Considering the 
heterogeneity of epilepsy, large numbers are needed to evaluate subgroups like seizure type 
and aetiology. Such studies are scarce. Few studies had used the guidelines for 
epidemiological studies on epilepsy from ILAE (Commission, 1993, 1997), prevailing at the 
time of the start of the Stockholm Incidence Registry of Epilepsy (SIRE) (see methods).  
2.3 EPILEPSY IN CHILDREN 
Epilepsy in children is a heterogeneous disease where the consequences are very diverse. As 
with any disease in children, it affects the whole family. Some parents experience a feeling of 
their child dying in front of their eyes at the time of the first seizure, which makes support 
and information to the family extremely important. The unpredictability of the disease, in 
  9 
combination with the parental concern due to the disease, complicates the child’s process of 
independence, especially for adolescents.  
There are several different syndromes within the concept of epilepsy, and many of them have 
a childhood onset. Identification of an epilepsy syndrome gives information regarding 
responsiveness to antiepileptic drugs (AEDs), long-term prognosis and possible associated 
comorbidities. Some of the epilepsy syndromes are considered easy to treat and transient, 
while others demand lifelong treatment and the children will, in spite of many antiepileptic 
drugs, live with daily seizures. Studies using the current classification have been able to 
define a syndrome in about 30–40% of children with epilepsy (Aaberg et al., 2017b; Wirrell 
et al., 2011).  
Seizure types in children seem to alter distribution with the age of seizure onset, but focal 
seizures are predominant in all age groups. Seizures are more often described as unclassified 
in younger children, and in these age groups multiple seizure types are found more often as 
well. Spasms were only seen in those younger than two years old (Aaberg et al., 2017b). 
The aetiology of epilepsy in children is more often unknown, and has a different pattern of 
known causes than epilepsy in adults (Dahl-Hansen et al., 2019). The aetiology also varies 
between different age groups during childhood. A large population-based cohort study found 
a specific aetiology in one third of the children. The most common, known aetiologies, found 
were ‘genetic’ (known or presumed) and ‘structural’. Children with seizure onset before the 
age of one, more often had a structural-metabolic cause, and less often an unknown cause 
compared to older children (Aaberg et al., 2017b). 
Febrile seizures appears in 2–5% of children between three months and five years 
(Vestergaard et al., 2006). Febrile seizures are not epilepsy and the seizures are self-limited, 
around the age of five. A few of these seizures turn out to have been the first seizures in a 
later epilepsy syndrome, were seizures are provoked by fever (Dreier et al., 2019). 
In a heterogenic disease like epilepsy in children, large studies are needed to detect different 
factors affecting the prognosis. It is also important to study this in a cohort with incident 
cases and a validated diagnosis. These limitations have been found in many previous studies.    
2.3.1 Epilepsy in children – comorbidity 
Epilepsy is a disease with a high presence of comorbidities. Comorbidity means that a disease 
coexists in patients with another disease, more often than by chance. The comorbidity might 
be the cause of the other disease through biological mechanisms, or a consequence of it due 
to a specific lifestyle reliant upon the disease or by adverse effects of the treatment of the 
disease or the diseases can have a common aetiology/pathogenesis. Knowledge of 
comorbidities is important when discussing the burden of the disease, treatment, prognosis 
and aetiology (Valderas et al., 2009). 
 10 
The type of comorbidities differs in different ages depending on the nature of the 
comorbidity, and between different epileptic syndromes. Overall, though, children with 
epilepsy have a high burden of neurological, as well as psychiatric and other somatic 
comorbidities (Berg et al., 2011a; Davies et al., 2003; Gaitatzis et al., 2012; Lin et al., 2012). 
An elevated association between epilepsy and all the major 21 WHO disease classes has been 
shown  and almost 80% of children with epilepsy have been found to have one or more 
comorbid diseases (Aaberg et al., 2016; Jennum et al., 2017). Predominant neurological 
disorders are headaches, cerebral palsy and neurologic congenital malformations. 
Neurodevelopmental or psychiatric comorbidities have been found in over 40% of the 
children with epilepsy with behavioural/emotional disorders, ADHD, intellectual disability, 
autism spectrum disorder (ASD) and unspecific neurodevelopmental delay as the most 
common (Aaberg et al., 2016; Reilly et al., 2014). Somewhat surprisingly somatic 
comorbidities are also very common in children with epilepsy, with gastrointestinal disorders, 
congenital non-neurological malformations and musculoskeletal disorders ranking high. A 
large population-based study including over 6000 children with epilepsy, reported that over 
13% had one or more neurological diseases as well as a psychiatric and a somatic disease, 
together with their epilepsy. (Aaberg et al., 2016).  
Psychiatric comorbidities have a stronger negative association with patients’ quality of life 
than seizure frequency (Baca et al., 2011; Boylan et al., 2004; Ekinci et al., 2017). 
Comorbidities might also affect the treatment of seizures, through drug interactions and 
through complicating seizure-preventive actions such as good sleeping habits and adherence 
to antiepileptic drug treatment. Many of the comorbidities have an elevated risk of premature 
mortality, as has epilepsy, and a combination have been reported to have a negative 
synergetic effect on mortality (Jennum et al., 2017; Thurman et al., 2017). 
Even though comorbidity is common in children with epilepsy, the heterogeneity of the 
disease makes the need for large cohorts to be studied in order to describe associations. Since 
there has been a discussion regarding the chicken and the egg of seizures and comorbidities, 
comorbidities need to be studied in incident seizure cases. This was previously done in a 
limited extent.   
2.3.2 Epilepsy in children – treatment and prognosis 
Epilepsy is in many cases a self-limiting disease and there are suggestions that children with 
epilepsy under certain circumstances could be left untreated (Arts et al., 2019). However, 
most children with epilepsy will start treatment with AEDs. It is known that some AEDs 
work better in some epileptic syndromes, but attention to the potential adverse effects of the 
drugs and the child’s potential comorbid challenges needs to be considered as well. The most 
commonly reported side effects of AEDs in children are fatigue, depression and cognitive and 
behavioural side effects (Guilfoyle et al., 2018; Ulate-Campos and Fernandez, 2017). In spite 
of well-chosen AEDs, in correct doses, 20-30% of the children will still have seizures more 
often than once a month (Forsgren et al., 2005; Sidenvall et al., 1996). Adverse effects of the 
AEDs and pharmacoresistance (tried multiple AEDs without seizure remission) is more 
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common in children with comorbidities (Ackermann and Wilmshurst, 2015; Ulate-Campos 
and Fernandez, 2017; Wirrell, 2013). Children who are pharmacoresistant should be 
considered for alternative treatments, such as a ketogenic diet and epilepsy surgery. The long-
term seizure remission in children depends on the epilepsy syndrome, comorbidities, age at 
seizure onset and aetiology. The majority of those with childhood-onset seizures will be 
seizure-free by adulthood, but those who don’t achieve remission has an increased risk of 
death. However, epilepsy is more than seizures and other outcome measurements, such as 
level of education, employment and likelihood to become married are affected long after 
seizure remission and the termination of medical treatment (Sillanpaa et al., 1998). Different 
social outcomes and premature mortality, are also dependent on the child’s socio-economic 
situation (Camfield et al., 2016; Nicoletti et al., 2009; Sillanpaa et al., 2014; Thurman et al., 
2017). 
Prognosis of epilepsy in relation to both neurodevelopmental comorbidities and CP was 
previously described to a limited extent, and the association with these comorbidities and the 
amount of AEDs, neuroleptics, antidepressants and drugs for ADHD dispensed to children 
with epilepsy was previously not assessed. 
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3 AIMS 
3.1 OVERALL AIM 
To describe the incidence of unprovoked seizures and the prevalence of neurodevelopmental 
comorbidities and CP in children with newly diagnosed seizures, and to increase the 
knowledge regarding the comorbidities’ implication on seizure freedom and future drug use. 
3.1.1 Specific aims 
I: To determine the incidence of new onset unprovoked seizures in the Stockholm population, 
and to classify these seizures according to the, at the time, prevailing ILAE’s guidelines. 
II: To examine the incidence of unprovoked seizures in children, and the prevalence of 
neurodevelopmental comorbidities and/or CP at the time of a first unprovoked seizure.  
III: To assess the prevalence of neurodevelopmental comorbidities and CP two years after a 
first unprovoked seizure, and to evaluate the overall probability of being seizure-free at that 
time, with or without AEDs, and in relation to neurodevelopmental comorbidities and CP. 
IV: To analyse the impact of comorbidities diagnosed at the time of seizure onset regarding 
later use of AEDs, antidepressants, neuroleptics and drugs for ADHD. 
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4 THESIS AT A GLANCE 
 
STUDY: AIM: METHODS: RESULTS: FINDINGS: 
I To determine the 
incidence of new 
onset unprovoked 
seizures in the 
Stockholm 
population, and to 
classify these 
seizures according 
to the, at the time, 
prevailing ILAE’s 
guidelines. 
Study population: Northern Stockholm 
(998,500 inhabitants). 
Inclusion criteria for SIRE: inhabitants of the 
area, seeking medical assistance for a first 
unprovoked seizure (index seizure), between 
Sept 1st 2001 and Aug 31st 2004 
Assessing: medical records from before, and 
up until 6 months after, the index seizure 
(baseline) regarding: classification of the 
seizures; risk factors; and aetiology. 
Statistics: Official population numbers were 
used to calculate the person years. Age- and 
sex-specific incidence rates, and age-adjusted 
rates using the European Standard Population 
were calculated. 95% CI was calculated using 
the Poisson distribution. 
1 015 patients (56% men and 58% with 
recurrent seizures at baseline) were 
included.  
*The crude incidence of a first 
unprovoked seizure and epilepsy was 
35.4/100,000 person years (95% 
CI: 33.3–37.6) 
*Seizures were classified as: partial 62%, 
generalized 9.8% and unclassified 
27.8%. 
*Presumed aetiology was present in 
37.6% of the patients, with stroke (11%) 
and brain tumour (9%) as the most 
common (primarily in adults). 
Neurological deficits from birth was 
found in 10.3%. 
The incidence of seizures 
was overall slightly lower 
than earlier findings, 
especially in the elderly, 
but with a similar 
distribution of gender, 
seizure type and aetiology 
indicating a sustainable 
method to identify 
incident cases. Seizure 
type and aetiology was 
decided on at a relatively 
low level, probably due to 
the dependence on 
medical records but also 
due to strict criteria for 
classification. 
II To examine the 
incidence of 
unprovoked 
seizures in children, 
and the prevalence 
of 
neurodevelopmenta
l comorbidities 
and/or CP at the 
time of a first 
unprovoked 
seizure.  
Inclusion criteria: Children, 28 days–18 years 
old, included in SIRE Sept 1st 2001 to Dec 
31st 2006. 
Assessing: seizure-incidence and baseline 
information on classification and aetiology of 
the seizures, and the prevalence of 
neurodevelopmental comorbidity and CP. 
Statistics: Official population numbers were 
used to calculate the person years. Age- and 
sex-specific incidence rates and prevalence’s 
were calculated. 95% CI was calculated using 
the Wilson score interval. 
766 children included, 56% boys and 
mean age 9 years. 
*The incidence of a first unprovoked 
seizure and epilepsy in children was 
67/100,000 person years (95% CI: 63–
72). Highest in the first year of life with 
204/100,000 person years. 
*A neurodevelopmental comorbidity or 
CP was found in 68% of the children 
(95% CI: 64–71%). More than one of the 
defined comorbidities was found in 1/3 
of the children. 
The incidence of seizures 
in children in Stockholm, 
Sweden was in accordance 
with other high-income 
countries. There was a 
higher prevalence of 
neurodevelopmental 
comorbidities and CP than 
expected in the general 
population already at the 
time of the index seizure. 
III To assess the 
prevalence of 
neurodevelopmenta
l comorbidities and 
CP two years after 
a first unprovoked 
seizure, and to 
evaluate the overall 
probability of being 
seizure-free at that 
time, with or 
without AEDs, and 
in relation to 
neurodevelopmenta
l comorbidities and 
CP. 
Patients – see Study II. Data baseline data and 
2-years data (information from baseline + 24 
months following the index seizure or start of 
treatment with AEDs). Documentation of 
seizures during month 13–24 after index, or 
after initiation of AEDs was defined as lack of 
remission.  
Statistics: Associations between baseline 
characteristics and remission were assessed by 
odds ratios (OR), estimated by logistic 
regression (OR, 95 % CI). 
750 children, 56% boys.  
*The comorbidities were as prevalent at 
baseline as at 2-years, with the same 
distribution. 
* More than 2/3 of all children were 
seizure-free month 13–24.  
* Lack of remission was almost three 
times as common in children with a 
neurodevelopmental comorbidity or CP 
compared to those without (OR: 2.87, 
95% CI:2.07–3.99). Lack of remission 
with comorbidity, and treatment with 
AEDs, was twice as common as for those 
without a comorbidity with AEDs 
(OR: 1.9 (95% CI: 1.4–2.6). 
The prevalence of 
neurodevelopmental 
comorbidities and CP 
remains the same the first 
two years of a seizure 
disorder, coherent with the 
thought that the 
comorbidities and the 
seizures have a common 
cause. 
Less children with 
neurodevelopmental 
comorbidities and CP 
attained remission of 
seizures indicating a more 
complex brain disorder.  
IV To analyse the 
impact of 
comorbidities 
diagnosed at the 
time of seizure 
onset regarding 
later use of AEDs, 
antidepressants, 
neuroleptics and 
drugs for ADHD. 
Patients and baseline data– see Study II. 
SIRE was linked to the Swedish Prescribed 
Drug Register (SPDR) from June 2005 (start of 
SPDR) until Dec 2014 to identify dispensing of 
AEDs and ADHD medication, antidepressants 
and neuroleptics by use of ATC codes.  
Statistics: Associations between baseline 
characteristics and drugs dispensed were 
assessed by odds ratios (OR) estimated by 
logistic regression (OR, 95% CI). The 
association between baseline characteristics 
and coming off AEDs was assessed by hazard 
ratios (HR), estimated with cox proportional 
hazard regression (HR, 95% CI). 
769 children (56% boys) were studied for 
a median of 10 years after index  
* Eight years after the index seizure, 
31% of all the children were still 
dispensing AEDs, four times more often 
to children with neurodevelopmental 
comorbidity or CP compared to those 
without (OR: 4.0 95% CI: 2.9–5.6). 
* Few children received neuroleptics, 
antidepressants or drugs for ADHD (1–
5%), more to those with a comorbidity. 
This was still 2–10 times more than what 
was dispensed in the general population.  
Only 1/3 of the children 
used AED after 8 years 
and only a few received 
drugs for ADHD, 
neuroleptics or 
antidepressants. There was 
a negative association 
between 
neurodevelopmental 
comorbidities and 
particularly CP at the time 
of the index seizure and 
long-term medication with 
AEDs, neuroleptics and 
drugs for ADHD. 
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5 METHOD 
5.1 STUDY POPULATION AND DATA COLLECTION 
The Stockholm Incidence Registry of Epilepsy (SIRE) included patients of all ages who 
sought medical advice for, what was concluded to be, an unprovoked seizure (hereafter, the 
index seizure).  The catchment area was an urban area, the northern part of Stockholm, with 
approximately 1 million inhabitants at the time of the inclusion of patients (close to 230,000 
individuals younger than 19 years old). The surveillance system was up and running from 
September 1st 2001. Children with seizures living in the area were continued to be included 
until December 31st 2006.  
The catchment area was served by three hospitals, but only the Karolinska University 
Hospital had departments of neurology, neurosurgery and paediatric neurology and there was 
also one central electroencephalography (EEG) laboratory reviewing all the EEGs from the 
area. Patients were identified through reading the EEG requests to the neurophysiological 
department, as well as screening of medical records at the department of Paediatric 
Neurology and Neurology at the Karolinska University Hospital for patients for the first time 
discharged with an International Classification of Disease (ICD) code of G40, G41 or R56.8. 
New referrals to the Neuro-oncology section and records from the paediatric emergency room 
records at the Karolinska University Hospital were also reviewed. A network with all 
neurologists, paediatricians and geriatricians, as well as nursing homes in the area was 
organized. They were asked to send the project coordinator a letter with the date, their own 
name and institution and the unique Swedish personal number of any potential case. 
5.2 PROCEDURES 
All relevant medical records of the patients, from before and up until six months after, the 
date of the potential index seizure were collected by the project coordinator. If the patient was 
included, this was the source of the baseline information about the patient. The medical 
records were evaluated by at least two members of a panel (neurologist T.T, 
neuropeadiatrician P.Å., and at the time a resident in neurology, C.A., and a resident in 
paediatrics E.Å.) and re-reviewed at least once in order to ascertain the consistency of 
application of the classifications. Patients who sought medical assistance for the first time for 
a first unprovoked seizure within the inclusion dates (Study I: September 1st 2001 through to 
August 31st 2004; Study II−IV: August 31st 2001 through to December 31st 2006), were 
living in the designated area, and for Study II-IV were younger than 19 years old (hereafter, 
children) at the time of the index seizure, were included in the cohort. Having been diagnosed 
with, or treated for, unprovoked seizures within five years prior to the index seizure was an 
exclusion criterion. For the children, medical records continued to be retrieved and reviewed 
until 24 months after the index seizure, or 24 months after introduction of treatment with 
AEDs. This information, together with the baseline data gave the 2-year data. The time 
window was prolonged for those who received AEDs within two years from the index  
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Figure 2. Flowchart of Studies 
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seizure, to give room for assessment of the treatment effect. The number of AEDs tried 
within 24 months of initiation of treatment was counted. 
In Study IV the child cohort was linked to The Swedish Prescribed Drug Register (SPDR) 
(Wettermark et al., 2007) by the unique personal number assigned to every Swedish citizen. 
The SPDR has been available since July 1st 2005 and the children were linked with data 
regarding all their dispensed drug prescriptions in Sweden up until Dec 31st 2014. The drugs 
are classified corresponding to the Anatomical Therapeutic Chemical (ATC) Classification 
System and Study IV analysed the ATC codes: N03A (antiepileptic drugs; AEDs); N05A 
(neuroleptics); N06A (antidepressants); and N06BA 01, 02, 03, 04, 09, 12 (medications 
licensed for the treatment of ADHD).  
 
Figure 3. Timeline of Studies 
5.3 DEFINITIONS 
Information about the seizure type of the index seizure (generalized seizures, partial seizures, 
unclassified or multiple seizure (1981)) was retrieved on three levels within the timeframe for 
baseline information;  
Level 1: the semiology of the index seizure,                                                                          
Level 2: the semiology together with diagnostic investigations such as EEG and MRI,                                                                     
Level 3: information from Level 1 and 2 + the semiology of any additional seizures.  
The probable aetiology of the seizure was divided into the groups suggested by the ILAE at 
the time of the start of the registry: symptomatic (the consequence of a cerebral disease, this 
group was subdivided into static or progressive aetiology); cryptogenic (i.e. suspected, but 
not identified, underlying cause or lesion); idiopathic (i.e. specific epileptic syndromes with a 
presumed genetic basis); or of unknown origin. Whether there was a neurological deficit from 
birth was also identified (Commission, 1989, 1993, 1997). Potential risk factors and the most 
likely more specific aetiology (e.g. stroke, hypoxic ischaemic encephalopathies, 
chromosomal abnormalities) for the seizure were also assessed. 
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For the children, information about a priori decided neurodevelopmental comorbidities and 
CP was also extracted from the baseline information. Intellectual disability (ID), cerebral 
palsy (CP), autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder 
(ADHD) were defined according to corresponding ICD-10, while developmental delay, 
speech/language and learning difficulties and unspecified psychiatric disorder pertained to a 
wide variety of problems within each domain. Developmental delay was used for 
psychomotor delay in younger children. Speech/language and learning difficulties included 
children with speech disorders, dyslexia and substantial difficulties in school. Unspecified 
psychiatric disorder was used to describe problems for which the child had received help 
from a child psychiatry department. The comorbidities were classified as suspected if there 
was a distinct portrayal of the problem, but no complete investigation for a diagnosis, and as 
certain when the child had an ICD-10 diagnosis. This was done in order not to underestimate 
the diagnoses due to the long waiting times for work-ups present in Stockholm during this 
time period. In the analyses these groups were mostly combined. Since almost all of the 
children had visited the department of child neurology, where the physicians typically 
participate in neurodevelopmental and neuropsychiatric team assessments on a regular basis, 
a distinct problem description by them was considered credible. ESSENCE (Early 
Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations) is the 
acronym used for unspecific developmental problems in younger children (Gillberg, 2010). 
This was used in Study II and III. Children below six years of age, with suspected or certain 
problems pertaining to developmental delay, speech/language and learning difficulties, 
intellectual disability, ASD or ADHD, were grouped both with their individual comorbidity 
and in the ESSENCE group. ‘Any comorbidity’ corresponds to one or more suspected or 
certain comorbidities.  
In Study III, potential remission of seizures was studied. This was defined as no seizures the 
last 12 months out of the 2-year data (13–24 months after the index seizure or initiation of 
treatment).  
In Study IV, discontinuation of medication was defined as the last date of the dispensing of a 
group of drugs, followed by at least one year of no dispensing of the drug. 
5.4 STATISTICS 
Incidence rates of seizures (Study I-II) and prevalence of neurodevelopmental comorbidities 
and CP (Study II) were calculated with 95% CI. CIs were calculated using the Wilson score 
interval (Newcombe, 1998) and the Poisson distribution (Morris and Gardner, 1988). 
Estimates of population size used in the denominator of the incidence calculations (Study I-II) 
were based on official population numbers from Statistics Sweden (StatisticsSweden). The 
official size of the population in question was added at December 31st of each year studied. 
The total number of person years was estimated to 2,995,553 in Study I, where also age-
adjusted incidence rates were calculated with the European Standard Population as standard 
population. In Study II the total number of person years of the children was estimated to 
1,384,053.  
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The association between baseline characteristics and remission, as well as the number of 
AEDs tried among those who came to remission was assessed in Study III. Odds ratios (OR) 
with 95% confidence intervals were calculated by logistic regression for remission. Baseline 
characteristics studied were sex, age-group, single/recurrent seizures, type of seizures 
(symptomatic, cryptogenic or idiopathic), comorbidity yes/no, and type of comorbidity. The 
comorbidities were examined in the same model (i.e. mutually adjusted), and the ORs were 
adjusted for sex and age groups. 
The baseline characteristics sex, single/recurrent seizures, comorbidity yes/no, and type of 
comorbidity were in Study IV analysed regarding association with treatment with AEDs, 
neuroleptics, antidepressants and ADHD medication four and eight years after index. Also in 
this study ORs and CIs were estimated by logistic regression, and comorbidities were 
assessed both in relation to specific comorbidities (in the same model) and any vs no 
comorbidity. In Study IV the hazard ratio (HR) of discontinuing treatment with AEDs in 
children who received treatment between July 1st 2005 and Dec 31st 2014 was also assessed 
in relation to baseline characteristics. HRs and 95% CIs were estimated by cox proportional 
hazard regression and the HRs were adjusted for sex and age (Model 1) and for age, sex, 
single/multiple seizures, comorbidity yes/no, and date of index seizure (Model 2). 
Analyses in Study I-III were made in SAS 9.1 and 9.2 and Study IV in SPSS version 22. 
5.5 ETHICS 
The studies were approved by the Ethics Committee at Karolinska Institutet Stockholm 
Sweden (No 2005/979-31/4, 2008/507-31/2 and 2009/2046-31/2).  
When the information from medical research can be of value to a larger group of the 
population, this is considered to override the privacy and integrity of individuals, according to 
the principle of ‘the greatest good’ (beneficence). To be part of a register can for some have 
very negative associations and give a feeling of discomfort. This was one of the reasons why 
no individual consent was obtained. It also avoids patients to being reminded of a disease or 
an event which some have forgotten, or never knew of, for example due to young age. The 
matter of voluntary participation was fulfilled, since there is information about clinical 
quality registers at the hospitals (waiting room areas etc.) and a person can decline to be in 
them, and ask to be removed from them. When linking different registers, the information 
was anonymised and a serial number was used and information was aggregated on group 
levels and were not shown on an individual level. The research questions were set a priori and 
all data were handled in the way described in the ethical applications and not altered in any 
way. The information attainable from SIRE regarding incidence, comorbidity and different 
kinds of prognostic information of seizures is valuable from a socio-economic, resource 
planning and disease management perspective. This kind of information has been scarce in 
large population studies, which is why the beneficence of the community in this case is of 
considerable value. 
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6 RESULTS 
6.1 STUDY POPULATION 
Northern Stockholm is an urban area, with a significant immigration giving a mix of ethnical 
origins.  
Study I is based on all seizure patients included between Sept 1st 2001 and Aug 31st 2004 
(N=1,015, 56% men). The incidence rates had a bimodal distribution with highest incidence 
among the youngest and the oldest. Recurrent seizures already at baseline was found in 58%. 
The seizure types were classified as focal (62%), generalized (10%) and unclassified in 28%). 
Aetiologies were classified as idiopathic (8%), cryptogenic (54%) and symptomatic (38%).  
Study II-IV are based on the children included in SIRE Sept 1st 2001 until Dec 31st 2006. 
The number of children differs slightly (Study II: N=766, Study III: N=750, Study IV: N=769, 
56% boys in all three) due to 16 patients lost to follow-up (5 died) in the 2-year data 
assessment, and a few new, late, inclusions in the registry (for Study IV). The children were 
between 28 days and 19 years old, median 7 years (Figure 4), and 67% had recurrent seizures 
at baseline. The seizure types were classified as focal (50%), generalized (21%) and 
unclassified in 28%). Aetiologies were classified as idiopathic (20%), cryptogenic (53%) and 
symptomatic (27%). 
In Study IV, the follow-up of drugs dispensed was for a median of 10.3 years (range 0.11-
13.0). 
 
Figure 4. Distribution of the children in SIRE in different age-groups. 
6.2 INCIDENCE OF SEIZURES (STUDY I AND II) 
After three years, approximately 10,500 EEG referrals and 3,300 medical records had been 
screened for Study I, and the crude incidence rate of index seizures was found to be 
35.4/100,000 person years (95% CI: 33.3–37.6) and the age-adjusted incidence rate (using the 
European Standard Million) (National Cancer Institute, 2008) was 39.0 per 100.000 person 
years. The crude incidence for males was 40.4, and 30.7 for females. The highest incidences 
were found among the youngest and the elderly (Figure 5). Most of the seizures (54.4%) were 
classified as cryptogenic, while 37.6% were symptomatic (symptomatic static 21.7% and 
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symptomatic progressive 15.9%) and 7.9% were classified as idiopathic. Generalized-onset 
seizures occurred in 100/1015 patients, all younger than 50 years old. A presumed aetiology 
to the seizure was found in 382/1015 (37.6%) of the patients, more often among the elderly. 
Stroke (115/1015, 11.3%) and brain tumour (92/1015, 9.0%) were the most common 
aetiologies overall, while ‘other specified’ (including diagnoses such as arteriovenous 
malformation, periventricular leucomalacia, demyelinating disease, tuberous sclerosis, mesial 
temporal sclerosis, brain abscess and tuberculoma) (20/382, 5.2%) and cortical malformation 
(16/382, 4.2%) were the most common among those younger than 15 years. 
 
 
Figure 5. Incidence of epileptic seizures by age and sex, SIRE registry 2001-2004 (N=1 015). 
 
In children 0–19 years old (Study II) the incidence rate of seizures was 67/100,000 (95% 
CI: 63-72/100,000), highest during the first year of life (204/100,000) and lowest among the 
18-year-olds (30/100,000). Among 0–14 year-olds, an age-group commonly studied in 
children, the incidence was 74/100,000. The difference between boys and girls was small 
(Table 1).  Half of the index seizures (385/766) were classified as focal, while 163 (21%) 
were generalized and 218 (28%) unclassified. The most common known aetiologies were still 
‘other specified’ (5.0%) and cortical malformation (4.3%), but for 77.7% of those younger 
than 19 years old, it was not possible to determine the aetiology of the seizures. For the 247 
with a comorbidity at baseline it was possible to determine the aetiology in 49.4% of the 
children, still with ‘other specified’ (11.3%) and cortical malformation (9.7%) as the most 
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common causes, but closely followed by hypoxic ischaemic encephalopathy (9.3%), known 
chromosomal abnormality (8.1%) and stroke (6.9%). 
 
 
Table 1. Age- and sex- specific incidence rates (per 100 000 person years) of unprovoked 
seizures/epilepsy in Stockholm, Sweden Sept 1st 2001 through Dec 31st 2006. N=766. 
 
6.3 NEURODEVELOPMENTAL COMORBIDITIES AND CP IN CHILDREN WITH 
SEIZURES (STUDY I AND II) 
At baseline certain or suspected neurodevelopmental comorbidities or CP was found in 32% 
(95% CI: 29–35%) of the children (Study II), and at the 2-year follow-up this number was 
35% (95% CI: 32–88%) (Study III). The comorbidities were distributed in the same way in 
the age groups at baseline and 2-years, but the diagnosis had changed for some individuals 
(e.g. from developmental delay to intellectual disability) (Figure 6). At the 2-year follow-up, 
39 ‘new’ children were diagnosed with a comorbidity, while for 16 children (12 from the 
ESSENCE group) the diagnosis of a comorbidity was no longer valid. The comorbidities 
varied with the age at seizure onset, with one of the three most frequent comorbidities, 
developmental delay (22%, 95% CI: 19–25%) primarily seen in the younger ages, while the 
other two, speech/language and learning difficulties (23%, 95% CI: 20–26%) and intellectual 
disability (16%, 95% CI: 13–18%) were equally present in all age groups. CP was found in 
71/766 (9%) and most common among the 0–5-year-olds, while ADHD was found in 48/766 
(6%), primarily among 6–16-year-olds. In the older age groups ASD and ‘other psychiatric 
diagnosis’ were most common, ASD was found in 50/766 (7%) of the children and ‘other 
Age (years) Person years
0 34 637 13 58 71 204 160 - 258 37 208 146 - 286 34 201 139 - 281
1 66 705 17 56 73 109 85 - 137 37 108 76 - 149 36 110 77 - 152
2 63 907 14 26 40 62 44 - 85 25 76 49 - 112 15 48 26 - 79
3 60 908 21 29 50 82 60 - 108 31 99 67 - 140 19 64 38 - 100
4 58 716 9 34 43 73 52 - 98 33 109 75 - 153 10 34 16 - 64
5 57 095 14 24 38 66 47 - 91 16 54 31 - 88 22 79 49 - 119
6 56 620 26 30 56 98 74 - 128 35 120 83 - 167 21 76 47 - 116
7 57 240 17 28 45 78 57 - 105 22 74 46 - 113 23 82 52 - 123
8 59 078 16 36 52 88 65 - 115 31 102 69 - 145 21 73 45 - 111
9 61 025 13 31 44 72 52 - 96 22 70 44 - 106 22 74 46 - 112
10 63 203 11 23 34 53 37 - 75 18 55 32 - 87 16 51 29 - 84
11 64 924 11 23 34 52 36 - 73 18 53 31 - 85 16 50 28 - 82
12 65 876 14 16 30 45 30 - 65 18 53 31 - 84 12 37 19 - 65
13 65 335 6 20 26 39 25 - 58 13 38 20 - 66 13 40 21 - 69
14 64 168 8 22 30 46 31 - 66 17 51 30 - 82 13 41 22 - 70
15 62 205 12 12 24 38 24 - 57 14 43 24 - 73 10 32 15 - 60
16 60 135 10 22 32 53 36 - 75 18 58 34 - 92 14 47 26 - 80
17 57 751 12 15 27 46 30 - 68 11 37 18 - 66 16 56 32 - 92
18 55 945 10 7 17 30 17 - 48 14 48 26 - 81 3 10 2 - 32
Incidence 
rate
95 % 
Confidenc
e Interval
Combined 
(single 
seizures 
Incidence 
rate
95 % 
Confidenc
e Interval
Total Male Female
Single 
unprovoked 
seizures (n)
Epilepsy 
(n)
Combined 
(single 
seizures 
Incidence 
rate
95 % 
Confidence 
Interval
Combined 
(single 
seizures 
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psychiatric diagnosis’ in 19/766 (2%) (Figure 6). Two out of the five comorbidities ID, CP, 
ASD, ADHD and other psychiatric were diagnosed in 72/766 (9.4%) of the children, and 
three in 14/766 (1.8%) (Figure 7). More than one comorbidity was more common in boys and 
among those with recurrent seizures at baseline. 
 
Figure 6. Prevalence (%) of comorbidities at baseline and at 2 years after the index seizure (an 
individual could display more than one comorbidity and a change of diagnoses from 6 to 24 months). 
 
 
Figure 7. Combinations of comorbidities. Number of children (0-18 years) with combined 
comorbidities (suspected or diagnosed) at baseline. It is known that there is a high occurrence of 
comorbidity between epilepsy, ASD and ID, this figure shows the addition of a fourth comorbidity for 
10 of the children. ID=Intellectual Disability, ADHD= Attention Deficit Hyperactivity Disorder, 
ASD= Autism Spectrum Disorders, CP=Cerebral Palsy. (N=766). 
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6.4 NEURODEVELOPMENTAL COMORBIDITIES AND CP AND SEIZURE 
PROGNOSIS – SHORT TERM (STUDY III) 
Almost 70% of the children in SIRE were in remission months 13–24 after the index seizure, 
or after initiation of AED, boys as often as girls, but less so for those younger than eight 
years, compared to those 13–18 years old. Only 53% of the 239 children with comorbidities 
achieved this. During this time period 274/516 (55.4%) seizure-free children received AEDs 
(including 24/197 who had only had one seizure), while 221/234 (94.5%) of those with 
seizures received AEDs (Figure 8). One of the 234 children still seizing during month 13–24, 
had daily seizures and 10 had one to five seizures during that year. The others had six or more 
seizures or an unknown number of seizures. To have a comorbidity gave an odds ratio (OR) 
for having seizures during month 13–24 of 2.87 (95% CI: 2.07–3.99) compared to not having 
a comorbidity. Lack of remission with comorbidity, and treatment with AEDs, was almost 
twice as common as for those without a comorbidity with AEDs (OR: 1.9 (95% CI: 1.4–2.6) 
(Figure 8). ID, CP, ASD, ADHD and ESSENCE individually increased the risk for seizures, 
with CP and ESSENCE giving the highest ORs (Table 2).  
 
Figure 8. Seizure status months 13–24 after the index seizure/start of treatment with AEDs, in 
relationship to comorbidity (at baseline) and anti-epileptic treatment (AEDs). N=750. 
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ref=reference for the following OR 
Table 2. Odds Ratios for seizures during month 13–24 after the index seizure for all the children 
(N=750), in relationship to seizure frequency and comorbidity. 
 
6.5 TREATMENT WITH ANTIEPILEPTICS – LONG TERM (STUDY IV) 
According to the information in the SPDR, 350/769 (46%) used AEDs four years after index 
and 240/769 (31%) after eight years. Children with a neurodevelopmental comorbidity or CP 
at baseline were four times more likely to receive AEDs four and eight years after the index 
seizure, with the highest odds ratios for those with CP (after 4 years; 5.0, 95% CI: 2.6–9.4) 
and ADHD (after 4 years; 3.2, 95% CI: 1.6–6.3) compared to those without a comorbidity 
(Figure 9). Treatment with AEDs was as common in boys as in girls, while it was less 
common among those of a younger age at index, and more common for those with recurrent 
seizures at baseline. 
Analyses of the 473 children who were dispensed AEDs between the start of SPDR (July 1st 
2005) and Dec 31st 2014, showed that the probability of discontinuing the AED treatment 
(i.e. probable seizure remission) was similar in boys and girls and between those with single 
and recurrent seizures at baseline. However, children with neurodevelopmental comorbidities 
or CP at baseline were 60% less likely to discontinue their treatment (HR 0.4, 95% CI: 0.3–
0.6, adjusted according to model 1) (Figure 10) compared to those without comorbidities 
(similar in-between individual comorbidities). Children older than 13 years old at index had a 
lower chance of discontinuing treatment with AEDs than younger children. 
n/total (%) OR (95% CI)
Number of seizures the first 6 months
22/247 (9) ref
recurrent seizures 212/503 (42) 7.46 (4.63-12.02)
Comorbidity
121/511 (24) ref
113/239 (47) 2.87 (2.07-3.99)
85/159 (53) 2.42 (0.81-7.26)
82/169 (49) 1.30 (0.56-3.04)
57/112 (51) 2.24 (1.13-4.46)
40/66 (61) 5.03 (2.81-9.01)
26/51 (51) 2.72 (1.38-5.36)
24/48 (50) 3.29 (1.74-6.20)
7/19 (37) 2.44 (0.92-6.52)
60/99 (61) 5.12 (3.03-8.65)
49/205 (24) ref
60/99 (61) 4.79 (2.86-8.03)
not ESSENCE (<6-years-old)
ESSENCE
intellectual disability
cerebral palsy
autism spectrum disorder
ADHD
unspecific psychiatric disorder
ESSENCE
no neurodevelopmental comorbidity
neurodevelopmental comorbidity 
developmental delay
speech/language/learning problems
one seizure
SEIZURES DURING MONTH 13-24
AT BASELINE
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Figure 9. Proportion of children with unprovoked seizures with and without comorbidity receiving 
AEDs x years after the index seizure. N=769. 
 
 
Figure 10. Survival function for discontinuing AED medication1. N=473. 
1Analysis of all children SIRE (index dates between Sept 1st 2001 till Dec 31st 2006) who received AED any time after the 
index date and after the start of SPDR (July 1st 2005) up until Dec 31 2014. Adjusted for age and sex. 
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6.6 TREATMENT WITH ANTIDEPRESSANTS, NEUROLEPTICS AND DRUGS 
FOR ADHD IN CHILDREN WITH SEIZURES (STUDY IV) 
Drugs for treatment of ADHD were dispensed to 31/769 (4%) of the children in SIRE four 
years after the index seizure, and to 38/769 (5%) after eight years. This was the case more 
often for those with recurrent seizures than those with a single seizure at baseline. Those with 
any comorbidity, and in particular ADHD, were treated in a much higher proportion 
compared to those without comorbidities. The OR to be treated with ADHD medication four 
years after index was 16.5 (95% CI: 6.9–39.5) and eight years after index 8.8 (95% CI: 3.7–
20.8) for those with ADHD at baseline compared to those with no comorbidity (Table 3).  
Antidepressant were dispensed to 13/769 (2%) four years after index and to 23/769 (3%) 
eight years after index. Lower age was associated with fewer antidepressants dispensed while 
a neurodevelopmental comorbidity or CP at baseline indicated towards an association with 
more children receiving antidepressants (OR after 8 years; 2.3 95% CI: 1.0–5.5) (Table 3). 
Few children were treated with neuroleptics, only 10/769 (1%) at four years and 19/769 (2%) 
at eight years. Children with a neurodevelopmental comorbidity or CP at baseline were more 
likely to also receive this treatment compared to those without comorbidity (OR after 8 years: 
6.9, 95% CI: 2.4–19.8), especially those with autism spectrum disorder (OR after 8 years: 9.1, 
95% CI: 2.2–37.4) (Table 3). 
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Table 3. Comorbidities and number of children treated with neuroleptics, antidepressants, or with 
drugs against ADHD 4, and 8 years following a first unprovoked seizure in children. 
1Odds Ratios (ORs) adjusted for age groups and sex. 2Information abstracted from medical records covering six months’ post 
index seizure, and pertaining to pre-index seizure, index seizure, and any subsequent seizures within six months from the 
index seizure, and information on comorbidities. 
Total N N (%) OR1 (95% CI) N (%) OR1 (95% CI)
Number of seizures at baseline2
One seizure 255 3 (1) ref 3 (1) ref
Recurrent seizures 514 7 (1) 1.1 (0.3-4.4) 16 (3) 2.9 (0.8-10.3)
Comorbidity at baseline
Without comorbidity 519 1 (0.2) ref 5 (1) ref
With any comorbidity 250 9 (4) 22.2 (2.8-178.2) 14 (3) 6.9 (2.4-19.8)
Intellectual disability 119 4 (3) 2.4 (0.5-11.2) 8 (7) 2.0 (0.5-7.3)
CP 68 1 (1) 1.3 (0.1-14.6) 1 (1) 0.5 (0.1-4.8)
Autism Spectrum Disorder 50 2 (4) 1.8 (0.3-11.5) 7 (14) 9.1 (2.2-37.4)
ADHD 49 3 (6) 6.3 (1.2-33.5) 1 (2) 0.4 (0.0-3.9)
Total N N (%) OR1 (95% CI) N (%) OR1 (95% CI)
Number of seizures at baseline2
One seizure 255 7 (3) ref 11 (4) ref
Recurrent seizures 514 6 (1) 0.3 (0.1-1.0) 12 (2) 0.5 (0.2-1.1)
Comorbidity at baseline
Without comorbidity 519 6 (1) ref 12 (2) ref
With any comorbidity 250 7 (3) 2.8 (0.9-8.7) 11 (4) 2.3 (1.0-5.5)
Intellectual disability 119 2 (2) 0.5 (0.1-3.9) 3 (3) 0.5 (0.1-2.4)
CP 68 1 (1) 3.8 (0.3-53.5) 2 (3) 2.6 (0.5-14.3)
Autism Spectrum Disorder 50 1 (2) 1.2 (0.1-13.6) 2 (4) 1.8 (0.3-10.0)
ADHD 49 2 (4) 4.6 (0.7-30.0) 3 (6) 2.7 (0.7-1.4)
Total N N (%) OR1 (95% CI) N (%) OR1 (95% CI)
Number of seizures at baseline2
One seizure 255 6 (2) ref 9 (4) ref
Recurrent seizures 514 25 (5) 2.4 (1.0-6.1) 29 (6) 1.9 (0.9-4.1)
Comorbidity at baseline
Without comorbidity 519 4 (1) ref 15 (3) ref
With any comorbidity 250 27 (3) 18.0 (6.1-52.8) 23 (9) 3.6 (1.8-7.2)
Intellectual disability 119 6 (5) 0.7 (0.2-2.2) 4 (3) 0.5 (0.1-1.6)
CP 68 4 (6) 2.7 (0.8-9.7) 4 (6) 1.9 (0.6-6.2)
Autism Spectrum Disorder 50 4 (8) 1.2 (0.3-4.4) 1 (2) 0.2 (0.0-1.8)
ADHD 49 15 (31) 16.5 (6.9-39.5) 12 (24) 8.8 (3.7-20.8)
ADHD medication
4 years 8 years
neuroleptics
4 years 8 years 
antidepressants
4 years 8 years
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7 DISCUSSION 
With SIRE, a large population-based cohort of patients with newly diagnosed unprovoked 
seizures, was established. A crude incidence rate of a first unprovoked seizure of 67/100 000 
person years was found in children, the highest rate being before the first birthday. One-third 
of these children were identified having neurodevelopmental comorbidity or CP and two-
thirds had experienced recurrent seizures already at baseline. Two years later more than two-
thirds of the children had been seizure-free for 12 months with or without AEDs, while only 
50% of the children with neurodevelopmental comorbidity or CP at baseline achieved this. 
Eight years after the index seizure, children with comorbidity were dispensed AEDs four 
times as often as those without comorbidity. In addition, more neuroleptics and drugs for 
ADHD were dispensed to those with neurodevelopmental comorbidity or CP at baseline.   
7.1 DISCUSSION ON MAIN FINDINGS 
7.1.1 Incidence of seizures 
SIRE was set up to enable a long-term follow-up of a rather large population in a resource-
effective manner. This large number of patients with a first unprovoked seizure identified in 
an urban population gives possibilities for further studies using the public registries by the 
unique personal number of all individuals in Sweden. Additionally, at the time, the incidence 
of seizures had not been described in such a large population-based material.  
The overall incidences of all ages found in SIRE was lower than the 51–74/100,000 reported 
in other studies from Europe and the US, and this was particularly true in the elderly 
population (Fiest et al., 2017; Forsgren et al., 2005; Olafsson et al., 2005). However, the 
overall incidence in children was within the range of previous studies, which indicates a good 
ascertainment of the paediatric cases in the area. A slightly higher age-specific incidence for 
those younger than one year was detected. The incidence found for the first year of life has 
shown a tendency to increase also in other more recent studies (Aaberg et al., 2017a; 
Camfield and Camfield, 2015; Larsson and Eeg-Olofsson, 2006; Saarinen et al., 2016). There 
were more patients in the whole SIRE cohort with unclassified seizures than observed by 
others (Aaberg et al., 2017a) presumably due to: the short follow-up time; medical records 
being the only source of information (with no standardised work-up); and strict application of 
criteria for classification. However, the distribution of sex, seizure type and identified 
aetiologies in the whole SIRE cohort was consistent with other studies (Christensen et al., 
2007b; Gao et al., 2018; Jallon et al., 1999; Oun et al., 2003; Wang et al., 2019a; Zarrelli et 
al., 1999), which suggests that the methodology had no major selection bias when identifying 
the cases.   
7.1.2 Neurodevelopmental comorbidities and CP in children with seizures 
There have been concerns that seizures per se, or the antiepileptic treatment, might contribute 
to the increased prevalence of comorbidities in children with epilepsy. In contrast to epilepsy, 
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neurodevelopmental comorbidities and CP can usually not be given an exact starting date, 
which complicates the analysis. 
Neurodevelopmental comorbidities and CP were found in 32 % of the children in SIRE, 
already at the baseline assessment. This is similar to a Norwegian study, observing 
developmental and/or psychiatric disorders in 42.9% of children with epilepsy, which they 
compared to findings of only 6.6% with these disorders in the general population (Aaberg et 
al., 2016). Surprisingly, at the 2-year follow-up of SIRE the number of children with 
comorbidities did not increase much, which indicates that many of the comorbidities are 
possible to identify and diagnose already at seizure debut. This supports the idea of a 
common cause resulting in both seizures and the comorbidity, rather than the idea of a causal 
relationship between the two. A comorbidity between epilepsy and mood disorders has been 
found to have a relative negative impact on the patients’ quality of life and lead to an 
increased consumption of medical services (Cramer et al., 2003; Johnson et al., 2004; Kanner 
et al., 2010). A comorbidity has also been found to elevate the already increased risk of 
premature death in patients with epilepsy (Abdel-Mannan and Sutcliffe, 2019; Christensen et 
al., 2007a; Fazel et al., 2013).   
7.1.2.1 Seizures and cerebral palsy 
Cerebral palsy (CP) and seizures have traditionally been regarded as closely related, with 20–
45% of children with CP developing epilepsy (Cooper et al., 2017; Gabis et al., 2015; Odding 
et al., 2006). A Swedish population study found the prevalence of CP in children born from 
2007–2010 to be 1.96/1000 live births (Himmelmann and Uvebrant, 2018). A Norwegian 
registry study found the prevalence of CP to be 13.9% in children with epilepsy, giving an 
OR of 55.9 (95% CI: 50.4–62.0) compared to the general population (Aaberg et al., 2016). In 
Study II and III of this thesis the prevalence of CP was found to be 9%, which is elevated but 
still lower than other studies of children with seizures, which may be attributable to the fact 
that this cohort also includes children with only one seizure and not only those with a 
diagnosis of epilepsy. 
7.1.2.2 Seizures and ADHD 
ADHD has been found to be 2–7 times more common in children with seizures than in the 
general population, with a prevalence of 12–38% (Aaberg et al., 2016; Bertelsen et al., 2016; 
Brikell et al., 2018; Reilly et al., 2014). However, one study in children with epilepsy with 
good seizure control and without intellectual disability found a prevalence of ADHD of 6.9%, 
well comparable to the prevalence in the general population (Kim et al., 2012). Another study 
demonstrated that children with epilepsy had ADHD more often than the general population, 
and that the risk increased with early onset age of seizures, frequent seizures and treatment 
with multiple AEDs (Wang et al., 2019b). An association with specific epilepsy syndromes 
has also been seen, with symptoms of ADHD in Frontal Lobe Epilepsy, Childhood Absence 
Epilepsy and Childhood Epilepsy with Centrotemporal Spikes (Parisi et al., 2010). The low 
prevalence of ADHD found in Study II and III may partly be explained by incomplete 
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information in the medical records. Additionally, ADHD has been considered a diagnosis 
relevant primarily for school-aged children, and consequently part of the cohort was too 
young for a possible evaluation for an ADHD diagnosis. 
7.1.2.3 Seizures and intellectual disability 
Intellectual disability has been found to be 30 to 40 times more common in children with 
epilepsy compared to those without (Aaberg et al., 2016; Chiang and Cheng, 2014). The 
prevalence of intellectual disability in children with epilepsy has been reported to be as high 
as 40% (Oh et al., 2017; Reilly et al., 2014; Sillanpaa, 1992). The prevalence of 16% in Study 
II and III was thus lower than expected, but still elevated compared to a presumed prevalence 
of about 1% in the general population (Maulik et al., 2011; Westerinen et al., 2014). The 
explanation for the low number again probably being that there was no standard work-up in 
SIRE and the inclusion of young children. Only rarely is a diagnosis of intellectual disability 
confirmed before three years of age. The elevated rates of intellectual disability in children 
with epilepsy could possibly partly be attributed to the seizures in specific epilepsy 
syndromes like the ‘Epileptic Encephalopathy With Continuous Spike and Wave During 
Sleep’ (CSWS) syndrome and Landau-Kleffner syndrome (Besag et al., 2016b), but given the 
prevalence is already high at seizure debut in many studies the theory of a common cause to 
both seizures and intellectual disability seems more likely in the majority of cases. 
7.1.2.4 Seizures and autism spectrum disorder 
A clear association has been shown between autism spectrum disorders and epilepsy with the 
one disorder coexisting in up to 20% in the other, but the cause of this association is still to a 
large extent unknown and debated (Besag et al., 2016; Lukmanji et al., 2019; Strasser et al., 
2018). Autism spectrum disorder is more common among boys in the general population 
(3:1) and this is also the case in children with seizures and ASD. However, in a study of 
different types and groups of ASD, the strongest association with epilepsy was found among 
females with an intellectual disability (Jokiranta et al., 2014; Loomes et al., 2017). Autism 
has been found in about 5% of the children with newly diagnosed epilepsy, and in almost 
15% of the children with a new diagnosis of epilepsy and intellectual disability (Berg et al., 
2011b). In the present studies ASD was found in 6.7% of the children. Out of these 50 
patients, 34, or 68% were also found to have an intellectual disability. A point prevalence of 
6.2/1000 of ASD was reported in the general population in a study of pre-schoolers from 
almost the same catchment area as these studies (Fernell and Gillberg, 2010).  
There is an ongoing discussion regarding whether epilepsy in some cases can result in 
symptoms of ASD (Besag et al., 2016). Arguments are made that some children with ASD 
lose skills early in life and this might be caused by (subclinical) seizures. This has been 
hypothesized since studies have found epileptiform discharges in more than half of children 
with ASD without other symptoms of epilepsy, and treatment with AEDs sometimes 
normalised the EEG (Chez et al., 2006). However, no evidence has been found that this 
normalisation have any therapeutic effect on the core symptoms of ASD (Tharp, 2004). 
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Others suggest a common molecular pathway between epilepsy, ASD and intellectual 
disability since genetic defects as well as similar types of brain pathology have been found in 
the different disorders (Tuchman and Cuccaro, 2011). The high prevalence of autism (and 
intellectual disability) already at the onset of seizures in Study II and III suggest a common 
cause to the disorder rather than a causal relationship.  
 
 
Figure 11. Growth rings on a tree, by Eva Åndell Jason. Epilepsy is diagnosed in all ages, while 
some of the discussed comorbidities are more age-specific. 
 
7.1.2.5 Seizures and psychiatric diagnosis 
Depression and anxiety are other diseases found in a higher prevalence in children with 
epilepsy, than in the general population. Some studies have demonstrated a correlation 
between depression/anxiety and different seizure variables such as seizure control, age of 
seizure onset, polypharmacy with AEDs and the type of epilepsy, while others do not 
(Alfstad et al., 2016; Cianchetti et al., 2018; Davies et al., 2003; Kwong et al., 2016; 
Schraegle and Titus, 2017). Anxiety and depression are generally more common in girls, but 
the differences between boys and girls have been found to be smaller in adolescents with 
epilepsy (Jones et al., 2015; Reilly et al., 2014). Population-based studies in Sweden, 
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Denmark and Finland have also shown higher rates of psychosis in adults with epilepsy than 
in the general population (Adelow et al., 2012; Clarke et al., 2012; Qin et al., 2005).  
The 2.5% (19/766) paediatric patients identified with a psychiatric comorbidity in Study II is 
probably a sign of underassessment due to the assessment through medical records with 
limited information, and to the fact that there was no access to the records from child 
psychiatry at this time point. Over 70% of the children were also younger than 10 years old at 
the time of assessment, and most of the included diagnoses are very rarely diagnosed before 
that age.  
7.1.2.6 Seizures and ESSENCE 
A large group of children, 34% (107/315), with seizures and who were younger than six years 
old, had unspecific cognitive, developmental and learning disabilities grouped under the 
acronym ESSENCE (Gillberg et al., 2014). The concept of ESSENCE implies that children 
with ESSENCE probably will receive a more specific diagnosis later in life, but have more 
unspecific neuropsychiatric cognitive symptoms before they are six years of age. The 
prevalence of ESSENCE in the general population is estimated to be 5–7% (Gillberg, 2010). 
Contrary to other reports of ESSENCE, boys were not overrepresented in our material, in 
spite of boys having more seizures per se (Aaberg et al., 2017a; Gillberg, 2010). Unspecific 
problems in younger children were well described and documented in the medical records 
which facilitated identification with the ESSENCE method.  
7.1.2.7 Seizures and multiple comorbidities 
As discussed earlier, more than one comorbidity is commonly observed. This was found at 
baseline in 87/766 (11.4%) in Study II. A very large study analysing six million children 
regarding 12 neurobehavioral comorbidities found multiple comorbidities in 36% of children 
with newly diagnosed epilepsy compared to in only 8% of those without epilepsy (Oh et al., 
2017).  
Children with epilepsy and cognitive difficulties have been found to have stronger 
associations with depression, anxiety and autism than children with epilepsy ‘only’ (Aaberg 
et al., 2016; Buelow et al., 2003; Caplan et al., 2005). Children with epilepsy and psychosis 
have also been found to more often have other comorbid neurodevelopmental diagnoses (like 
autism and intellectual disability) than children with psychosis only (Lax Pericall and Taylor, 
2010). As mentioned earlier in this discussion, these results support the hypothesis of a 
common cause to the different disorders. 
7.1.3 Seizures - prognosis and treatment 
7.1.3.1 Seizure prognosis – short term 
In Study III seizure freedom during month 13–24 after the index seizure, or the start of 
treatment with AEDs, was studied. Of the 750 patients, 69% were seizure-free in year 2, with 
or without treatment. A negative impact on seizure freedom was seen in those with 
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neurodevelopmental comorbidities and CP at index, and for those who had had already more 
than one seizure at the baseline assessment. This confirms earlier findings regarding 
comorbidities and recurrent seizures close in time to seizure debut (Brorson et al., 2019; 
MacDonald et al., 2000; Tsubouchi et al., 2019), likely reflecting that epilepsy often is one of 
a variety of symptoms in children with neurological disturbances, and that comorbidities 
imply a more severe disturbance of the brain function. This agreeing with the concept that 
children with multiple diagnoses have a more complex phenotype of an underlying cause 
(Tuchman and Cuccaro, 2011). 
7.1.3.2 Treatment with AEDs – long term 
According to the current definition epilepsy is first resolved after 10 years without seizures, 
and at least five years without treatment (Fisher et al., 2014). Less than 50% of all the 
children in SIRE were dispensed AEDs four years after index, and one-third after eight years. 
However, after eight years, half of those with any comorbidity were still dispensed AEDs. 
Between Sept 1st 2005 and Dec 31st 2014, there was a 40% lower chance that those with any 
comorbidity discontinued medication, compared to those without comorbidity. Assuming that 
most of these children stopped using AEDs due to seizure freedom indicates a rather good 
overall long-term seizure prognosis in children. Similar results have indeed been reported by 
others (Moosa, 2019). Furthermore, from the perspective of this endpoint a negative influence 
of neurodevelopmental comorbidity and CP and repeated seizures at baseline could be seen. 
This confirming other studies where seizure frequency, aetiology and IQ during the first years 
of the seizure disease influenced the future remission of childhood epilepsy (MacDonald et 
al., 2000; Sillanpaa et al., 2014; Tsubouchi et al., 2019). This once again stresses the 
importance of evaluating children with seizures for neurodevelopmental comorbidities and 
CP. 
7.1.3.3 Treatment with antidepressants, neuroleptics and drugs for ADHD in children 
with seizures 
After studying the prevalence of different comorbidities in children with seizures, an 
evaluation of pharmacological drug treatment of some of these disorders was performed.  
Study IV found that surprisingly few children from SIRE were treated with neuroleptics (1–
2%), antidepressants (2–3%) or drugs for ADHD (4–5%). However, they were still dispensed 
2-10 times more frequently in this group of children with seizures, than what was reported 
from the official health statistics of all children 0–19-year-olds in the county of Stockholm, 
Sweden. Neuroleptics were dispensed to 1.4/1000 of 0-19 year-olds in the general population 
of Stockholm in 2006 (the first year with complete data in SPDR) and to 2.34/1000 of them 
in 2014 (the last year of follow-up of the SIRE cohort). At the same time points, 
antidepressants were dispensed to 4.6/1000 (2006) and to 9.9/1000 (2014), and drugs for 
ADHD to 4.3/1000 (2006) and to 22.2/1000 (2014) of the children in the general population.  
When an individual suffers from two different disorders, one of the diseases may gain 
precedence over the other, leading to the underassessment and no treatment of the other. 
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Many things may influence the use of medical treatment of the seizures, as well as the 
comorbidities. Drugs for comorbidities might lower the threshold for seizures, there can be 
interactions between the drug for the comorbidity and AEDs, and symptoms of depression 
and anxiety have been seen as adverse effects of many AEDs (Kanner and Dunn, 2004; Mula 
and Sander, 2007). When more than 100 children with epilepsy were evaluated for 
psychiatric disorders, 2/3 had a psychiatric diagnosis, but only 1/3 received any mental 
service (Ott et al., 2003).  Many guidelines, including those from the Swedish Medical 
Products Agency (MPA) (Läkemedelsverket, 2016), recommends caution with treating 
ADHD with methylphenidate in children with seizures. This is in spite of consistent findings 
and conclusions that there is no evidence that drug treatment of ADHD in children with 
epilepsy causes seizures (Besag et al., 2016a; Brikell et al., 2019; Gucuyener et al., 2003; 
Hamoda et al., 2009; Parisi et al., 2010) . Treatment of depression with selective serotonin 
reuptake inhibitor (SSRI) and serotonin–norepinephrine reuptake inhibitors (SNRI) has 
instead shown to potentially decrease the risk of seizures (seizures were in this study not 
defined as epileptic, but as not provoked by an identifiable factor like alcohol withdrawal, and 
with a possible relationship to the drug studied) (Alper et al., 2007). Some neuroleptics used 
for treatment of psychotic symptoms in children with epilepsy may decrease the seizure 
threshold (Hedges et al., 2003; Jerrell and McIntyre, 2008; Kumra et al., 1996; Remschmidt 
et al., 2000), but risperidone used to treat behavioural disorders in 54 children with epilepsy 
gave no changes in seizure frequency (Holzhausen et al., 2007). 
7.2 DISCUSSION ON METHODOLOGY 
The scientific value of a study is based on its internal and external validity. To be reliable and 
of interest to others, the study should have measured what it was supposed to measure 
(internal validity) and the results should be generalizable to other populations than the one 
studied (external validity).  
Large, well performed randomised controlled trials (RCTs) provide the strongest evidence for 
causal associations and are crucial for the formulation of clinical recommendations. However, 
non-randomised observational studies, like cohort studies and case-control studies, can 
sometimes be the only possible or optimal design (Rothman, 2012). This is, for example, the 
case when the outcome is rare or when ethical issues prevents RCTs.  
7.2.1 Random error 
Errors exists in all studies; they can be random and give the results a low precision. Precision 
is affected by the size of the study population and the choice of study design. The precision of 
a statistic estimated within in a study can be described by the confidence interval. The 
interpretation of a 95% confidence interval is that if we used the same method with a 
different sample from the same underlying population, and compute an interval estimate for 
each sample, we would expect the true population parameter to fall within the interval 
estimates 95% of the times (Rothman, 2012). 
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The fact that this thesis is based on a relatively large registry gives the studies fairly good 
precision regarding incidence of seizures. Still, within subgroups of specific comorbidities, 
and for estimation of associations with specific treatments including AEDs, neuroleptics, 
antidepressants and drugs for ADHD the numbers were sometimes small which is reflected 
by wide confidence limits around the OR and HR estimates, making the results uncertain. 
Furthermore, due to small numbers, we could not analyse specific epilepsy syndromes 
separately. 
7.2.2 Systematic errors  
Errors can also be systematic and lead away from the correct answer. Systematic errors are 
also called ‘bias’ and includes selection bias, misclassification and confounding. 
7.2.2.1 Selection bias 
Selection bias is when the studied population differs from the source population and can be 
due to patients with problems being more willing to answer a questionnaire, a drug treatment 
leading to more medical visits and then giving a higher frequency of detected problems or 
admission rate bias where individuals with many diagnoses are more often found in patients 
at a hospital (Rothman 2012). Such selection bias may influence generalisability of the results 
to the underlying population and also distort associations between investigated exposures and 
outcome. 
For all of SIRE there was a likely underassessment of seizure patients among the elderly, due 
to a larger number of potential caregivers in the area. The assessment at the hospital 
departments was done by the research nurse, but there are difficulties in keeping a large 
network with many caregivers reminded of the task to submit cases and some might have 
been unwilling to report cases due to lack of time. However, the risk of underassessment of 
children seems substantially smaller. The standard practice in the area was to refer children 
with seizures to the neuropediatric department at Karolinska University Hospital, even 
though a few patients might have been referred to other hospitals or stayed at an outpatient 
clinic outside the hospital. With regard to adults, and particularly the elderly, there were more 
alternatives for seizure care. Also some patients had their index seizure in other cities, when 
travelling, but most of them were identified by SIRE when referred for follow-up to their 
‘home hospital’ in Stockholm. Nonetheless, the cases had a similar composition regarding 
sex, seizure type and aetiology as seen in other studies (Christensen et al., 2007b; Gao et al., 
2018; Jallon et al., 1999; Oun et al., 2003; Wang et al., 2019a; Zarrelli et al., 1999), which 
suggests that selection bias was minor in SIRE. The potential underassessment will lead to 
underestimated incidence particularly in Study I (all ages), but may also be an issue in Study 
II (children).  
The prevalence of comorbidities might be over-estimated, since children with more than one 
medical problem may be examined by medical professionals more often, and questions 
regarding symptoms of seizures might be discussed and incident seizures be identified and 
more children with comorbidities might be included in SIRE in this way. Compared to the 
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general population children with seizures have more frequent medical visits, why 
neurodevelopmental comorbidities and CP might be recognized more often. This may to 
some extent contribute to the large differences in the prevalence of such comorbidities 
observed between the children included in SIRE and the general population (Study II). 
Loss to follow-up can introduce selection bias if those remaining in the study had a different 
level of exposure e.g. prevalence of comorbidities/ or outcome, e.g. prognosis, then those not 
staying in the study. Importantly, there was virtually no loss to follow-up in the 2-year 
follow-up, minimizing potential selection bias (Study III). Moreover, a particular advantage 
of using registry data for follow-up (Study IV), is it can be expected to be complete for all 
participants.  This is true for the Swedish Prescribed Drug Register which covers all 
dispensed medications in Sweden. 
7.2.2.2 Misclassification bias 
Misclassification bias is introduced when the measurements are incorrect, so that some 
persons who have a disease of interest (or exposure) are classified as not having the disease or 
vice versa. 
Misclassification of seizures;  
All data were assessed in a standardised way, according to the predefined research protocol 
(which was based on the prevailing ILAE recommendations (1981, 1993)) and all medical 
charts were read by at least two members of the research group in order to strengthen the 
internal validity. To have a first seizure, and not a diagnosis of epilepsy, as the inclusion 
criteria strengthens the internal validity, since the diagnosis may be delayed in the clinic and 
the definition of epilepsy has changed over time. A first diagnosis of epilepsy as inclusion 
criteria might include children who have been having seizures for quite some time, which 
could tamper the outcome. However, not everyone seeks medical assistance already at the 
first seizure (might be a short event not really attended to, until more have happened). In 
SIRE as many as 25% were assessed to have had, at least one, probable, unattended, 
unprovoked seizure already before the index seizure (the first one for which the patient 
sought medical assistance). The seizure diagnosis, of the index event, was decided on, and re-
evaluated, by the research team so as to consistently validate the diagnoses. 
Being dependent on medical records as the source for information, but with no influence over 
the quality of the records or what procedures had been followed, such as EEG, is a limitation. 
As an example, the low rate of performed neuroimaging could affect the reliability of the 
seizure types and the aetiological classifications, but the presumed aetiologies found, agreed 
with findings from other studies (Aaberg et al., 2017b; Gao et al., 2018; Hirfanoglu et al., 
2017; Olafsson et al., 2005; Wang et al., 2019a). Medical records as the data source might 
lead to some non-differential misclassification towards ‘unknown’, especially since the 
research team used classifications of seizure type strictly. The relatively short follow-up time 
of six months used for baseline information probably also led to some misclassification, since 
it is not always possible to make seizure classifications in that time. Misclassification 
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regarding seizure types and aetiology could be both differential and non-differential in these 
studies; EEG and brain imaging were possibly performed more often in children with a 
comorbidity, and could then overestimate the specific classifications in that group. 
Misclassification of comorbidities;  
With regard to comorbidities, no formal assessment was made of the patients with suspected 
comorbidities, which gives an uncertainty for some of the diagnoses. Instead this information 
was based on a clear problem description in the medical records. This was a choice made to 
avoid a substantial underassessment due to the long waiting times for neuropsychological 
evaluation at the time. Access to records from child psychiatry was restricted, which meant 
that knowledge of a clinic assessment was dependent on information from the parents to their 
career. At the 2-year follow-up comorbidities were found in 8% of children not diagnosed 
with comorbidity at baseline, and in 2% (n=16) of the children the diagnosis of comorbidity 
was no longer valid, showing good consistency (12/16 children belonged to the ESSENCE 
group). 
Assessment of neurodevelopmental comorbidities and CP at baseline were based on data at 
the time of seizure onset and the following six months. Based on this we find it unlikely that 
they were caused by longstanding exposure to a seizure disorder or treatment with AEDs. It 
should however be mentioned that 25% of the children had experienced seizures before the 
one for which they sought medical assistance (the index seizure).  
When reading medical journals, information might be interpreted in different ways by 
different individuals (interviewer bias). To reduce this potential bias, more than one person 
assessed all medical journals.  
Misclassification of recurrent seizures;  
The information on the outcome seizure remission was also collected from the medical 
journals. Most patients had regular contact with their treating physician, either by visits or 
phone calls. Not all may be able to report the seizure frequency in a reliable way. This is 
probably more of a problem when the child had more frequent seizures, and the parents had 
difficulties remembering them all. On the other hand, parents to children with few seizures 
might also forget more frequent seizures more distant in time if reporting to the caregiver 
infrequently. Children with comorbidities might have had a more frequent contact with their 
treating physician, and then remembered to report more seizures, which might have made the 
association between co-morbidity and recurrent seizures during the 24 month follow-up 
stronger (Study III).  
Misclassification of drug treatment;  
Information of drug use in Study III was also assessed from the medical journals. This was 
drugs prescribed, which is known to be an over-assessment of drugs used since all drugs may 
not be collected by the patient. Children with comorbidities might have been treated with 
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other drugs as well, and poly-pharmacy increases the risk of non-compliance (Erickson and 
Yang, 2019; Ofori-Asenso et al., 2018) why drug use might have been overestimated in this 
group. Non-compliance might have made the association between the comorbidities and lack 
of seizure remission in Study III stronger. A strength in Study IV is that we can confirm the 
association between comorbidities and drug use with the Swedish Prescribed Drug Registry 
(SPDR). The data collection for SPDR is done by a state owned company responsible for the 
pharmaceutical services in Sweden, with the data collected from the prescription software, 
which reduces this risk. SPDR does not give information on drugs prescribed, but on drugs 
dispensed in other to reduce the effect of lack of compliance (Wallerstedt et al., 2016; 
Wettermark et al., 2007) (Study IV). 
In Study IV we also used information from the SPDR to retrieve information on neuroleptics, 
antidepressants and drugs for ADHD. The SPDR is available from July 2005, which is a 
limitation since the index seizures were collected already from September 2001. To have the 
same data on all the children, and to not include an unknown confounder, we chose to study 
drugs dispensed four and eight years after index.  
The fear of neuroleptics, antidepressant and drugs for ADHD, lowering the threshold for 
seizures might have decreased the number of drugs dispensed among these children with 
known seizures, compared to the general population.  
As mentioned earlier this group of children with seizures visit a neuropeadiatrician more 
often than the general population, and it is known that more frequent hospital visits lead to 
more drug prescriptions. This affects the comparison between drug treatment in children of 
SIRE and that of the general population of children. Within SIRE, the association between 
comorbidities and drugs dispensed might be overestimated for the same reason (Study IV).  
7.2.2.3 Confounding 
Confounding is a factor associated with both the exposure and outcome that is being studied. 
Failure to adjust for such a factor may result in spurious associations between exposure and 
outcome. E.g. being the youngest in the family is not the cause of Mb Down, it is a 
confounder in the association between maternal age at delivery and the risk of Mb Down in 
the child. 
Age and sex are often confounders, both seizures and most of the comorbidities studied are 
more common in boys. Incidences and ORs and HRs were calculated adjusted for age and 
sex.  When analysing the individual comorbidities, they were mutually adjusted, since they 
often covariates with one child having more than one comorbidity (Study III). When 
analysing the HR for discontinuation of drugs we adjusted additionally for single/recurrent 
seizures, comorbidity yes/no and date of index. Date of index was valuable since some 
children had their date of index years before SPDR was up and running, while others were 
included when SPDR was available.  
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Socioeconomic factors could also be a confounding factor, since some of the comorbidities 
are overrepresented in families with a lower income and education. Adherence to treatment 
with AEDs may be lower in children in families with low education, and this could result in a 
higher risk of recurrent seizures. It is also known that use of prescription drugs is higher in 
these groups (Weitoft et al., 2008). This may contribute to an association between 
comorbidity and future treatment with e.g. ADHD medication.  It is noteworthy that there 
was no association between the risk of unprovoked seizures and socioeconomic status (SES) 
or education in previous studies based on SIRE (Adelow et al., 2011, 2012; Mahler et al., 
2018). Unfortunately access to information regarding SES and parents’ education was 
incomplete in the younger age groups, why we could not adjust for SES. 
7.2.3 Generalizability 
Since these are large population-based studies with minimal loss to follow-up the external 
validity should be good and findings should be generalizable to other settings with a similar 
aetiological pattern for seizures, and similar treatment strategies as in Stockholm, Sweden.  
Health care is easy accessed in Stockholm, Sweden, and free of charge for children. 
Prescribed drugs were also heavily subsidized by the government (but not free of charge) 
during the study period. This might affect the generalizability regarding treatment, to other 
settings where the health care system differs. However, it should make the data regarding 
seizure incidence and prevalence of comorbidity more reliable since medical visits are less 
dependent on the family income. 
Treatment strategies regarding ADHD have shown great differences in different parts of 
Sweden, and also over time there has been a larger increase of children in Stockholm being 
treated compared to other counties (Socialstyrelsen). In the general population of Stockholm, 
the children were dispensed drugs for ADHD 5 times more often in 2014, than in 2005. This 
complicates the comparison with other settings and over time, but it should not affect the 
association between neurodevelopmental comorbidities and drugs dispensed. 
The association between neurodevelopmental comorbidities and CP and poor seizure 
prognosis should in large be generalizable to other settings. 
7.3 CONCLUSIONS 
 The incidence of unprovoked seizures in Stockholm is similar to that in other high-
income countries. The crude incidence rate of all ages was 35.4/100, 000 person 
years, with the highest incidences found among the youngest and the elderly. In 
children 0–19 years old the incidence rate of seizures was 67/100,000, highest during 
the first year of life (204/100,000). 
 The index-seizure was most often classified as focal (62% in all ages, and 50% in 
children). There was a comparably high amount of seizures that remained 
unclassified, probably due to short follow-up, dependence on medical records and 
strict application of classification criterias. However, the pressumed aetiologies found 
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were similar to other studies, with stroke (11%) and brain tumours (9%) being the 
most common causes. Neurological deficits from births was found in 10% of the 
patients. Many of these deficits are risk factors for the comorbidities studied. 
 A higher prevalence of neurodevelopmental comorbidities and CP was found in 
children with a first unprovoked seizure compared to what is seen in the general 
population. This supports the hypothesis that innate neurological disturbances are 
responsible for both the seizures and the other neurodevelopmental symptoms.  
 Neurodevelopmental comorbidities and CP at baseline had a negative association with 
seizure remission within two years, regardless of treatment with AEDs or not. 
 Children with neurodevelopmental comorbidities and CP at baseline were dispensed 
AEDs, neuroleptics and drugs for ADHD more often than what was dispensed in the 
general population, four and eight years after index.  
This supports the hypothesis that innate neurological disturbances are responsible for both the 
seizures and the other neurodevelopmental symptoms, and that neurodevelopmental 
comorbidities and CP have a negative effect on the prognosis of seizures in children. 
7.4 CLINICAL IMPLICATIONS 
With regard to neurodevelopmental comorbidities and CP it would contribute to the care of 
the patients if the neuropeadiatrician carefully screened for these types of diagnoses at the 
seizure debut. This is particularly so, since the comorbidities have a negative impact on the 
seizure prognosis, but also because the comorbidities addressed in this thesis merit specific 
management. The presence of comorbidities should also affect choices regarding treatment of 
the epilepsy, since more children in this group will be pharmacoresistant and also because 
more of them will use other drugs later on, increasing the risk of future potential drug 
interactions.  
The thesis stresses the magnitude of the burden of epilepsy, since in many cases it also 
includes the burden of one or more comorbidities. Both patients with seizures, and patients 
with neurodevelopmental comorbidities and CP, have elevated risks of morbidity and 
mortality, which is why adequate resources should be allocated for identification and 
management of the disorders. This is a large and vulnerable group of children who would 
benefit from interdisciplinary team assessments (Nickels et al., 2016). 
7.5 FUTURE PERSPECTIVES 
SIRE can be used for further long-term studies regarding seizures. Case-control studies 
regarding the use of other drugs such as analgesics, antibiotics and melatonin could shed 
more light on the burden of disease on patients with seizures. Combining SIRE with other 
health care registries in Sweden can provide information regarding health-care and social 
issues. With the children becoming adults, outcomes such as education, child-bearing, and 
causes of death can be studied. SIRE has previously been used with different diagnoses from 
the Hospital Discharge Registry as exposure and with accident and injuries as both the 
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exposure and as the outcome. Being as large as it is, the SIRE cohort can to some extent be 
divided into different subgroups regarding seizure types, aetiology and early comorbidities. 
Epidemiological studies like these give a helicopter perspective on the diseases studied. It 
would be of much interest to zoom in on the patients and validate the findings in a clinical 
context with, for example, an interview study of children with incident seizures in the area 
over a couple of years regarding neurodevelopmental comorbidities and CP. These children 
could later be included in a follow-up survey on seizure frequency and AED treatment. This 
would, of course, need new ethical approvals. 
From a wider perspective, the findings of this thesis are consistent with others suggesting an 
innate cause/s to a neurodevelopmental complex. A continued search for these possible 
causes with imaging studies, genetic studies, immunological studies, etc. could give new 
leads for future treatments of uncontrolled seizures as well as the symptoms of 
neurodevelopmental comorbidities and CP. 
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FoU Sörmland – tack för generöst finansiellt stöd, stöd av bibliotekarie och statistiker, och 
engagemang och uppmuntran kring forskning i stort.  
Tack även för generöst finansiellt stöd från Margarethahemmet och UCB Nordic. 
 
Alla barn och familjer jag får träffa – ni lär mig så mycket om livet och tacksamhet. 
Känner mig ödmjuk inför allt ni delar med er av. 
Arbetskamraterna både på Barn- och Ungdomskliniken och Habiliteringen i Nyköping 
– för att ni aldrig klagat (till mig) om min forskningstid, men framförallt, för allt ni kan och 
fixar! För att det är roligt att arbeta tillsammans med er, och all er kunskap! Och för alla 
roliga fester. 
Helena, Wafa, Fredrik, Magnus (jag låtsas som att ni inte har slutat), Faruk, Amerah – 
Nyköpings barn, det här är era riktiga superhjältar. Jag är stolt över oss, och allt vi fixar!  
Ulrika o Elin – som gör mina arbetsdagar roliga och rimliga! Som ser till att ”mina” 
patienter blir omhändertagna, även när jag inte är där. Mats – tänk att få ha dig som vikarie, 
vilken lyx. 
Björn – för att du introducerade mig i barnneurologin, och för Per, så att detta projekt 
startades upp. För att du alltid visat intresse för hela mig, och alltid stöttat.  
Barn – och Ungdomskliniken Sörmland - med Diana som alltid varit positiv till min 
forskning, Charlotte, som visat att det går och Dan som kommer efter, men ändå ligger långt 
före. Med Susanne, Ann-Sofie, Hilla, Rosie och Carina (de två sistnämnda iofs Hab) som 
löser allt sådant som jag inte fixar, och alltid frågar hur jag mår. Å alla ni andra! 
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ALB – kollegorna - Tack för alla skratt när jag jobbade med er. Och jag är så tacksam för att 
ni inte är längre än ett telefonsamtal bort, när det blir för klurigt. 
Uppsala-barnneurologerna och övriga i regionen – ni känns närmre och närmre. 
Ansiktena bakom remiss-svaren skiner igenom och det gör mig glad (och arbetet roligare).  
 
Lundafamiljen - ni är så många och det börjar bli alltför länge sen. Men; skål för glada 
minnen, skål för varje vår! Tack gymnasiegänget för minnen från nästan hela livet och tack 
studentlivsvännerna för den härligaste av tider! Jag tror att vår nästa vår närmar sig. 
Nypangänget – past, present and future. Resorna, skidresorna, onsdagarna, kräftskivor, 
surströmming, matlagningsgänget, tjejträffarna som blivit tantträffar (som blev tonårsfest), 
fester, jourer, paddlingar, hamnen, sommarstugor, terapisnack, snack isf gym, ridläger, tårar 
och skratt, och nu även en disputationskompis. Vad mer kan man begära? 
Övriga vänner – tänk vad mycket vi har hunnit med, trots att vi är så unga! Någon har jag 
känt hela livet, andra har jag sett världen tillsammans med och några ser jag barnen växa upp 
tillsammans med. Det som gäller er alla är att vi inte behöver ses ofta för att finnas för 
varandra! Jag vet att ni finns där. Det är stort.  
 
Mamma – för all stöttning och för att du alltid tror på mig! För allt du lyssnat på. För all tid 
du lagt ner, allt från multiplikations-memory till skjuts, från barnvakt till fester. Jag minns när 
vi åt kinamat sittandes på köksgolvet i Västerås. “Du och jag, Alfred! Du och jag, 
Emil!”(Astrid Lindgren). 
Pappa – för att du planterade drömmarna om studier och disputation, men med fokus på 
festerna och glädjen. Som alltid tror att allt går och vill att alla ska få göra roliga saker. Som 
alltid lyssnat när jag sagt till dig att göra det. Som inspirerar mina barn till att vara glada och 
se positivt på framtiden! 
Patrik – för att du alltid har kunnat förklara så att jag förstår, och som alltid förstår (även 
litteratur på forskningsnivå, långt utanför ditt eget område). Tack för smörgåsarna med 
isbergssallad o majonnäs. Och för att du såg till att jag slapp göra pianoläxan. Vad mer kan 
man begära av en storebror? 
Lena – för att du har gått före och banat vägen, för att du älskar mina barn, för många skratt 
och roligheter. För att du hjälpt mig med hemligheter. Och för att du hittade min man! Bättre 
syster går inte att få! 
Lukas – för att du höll mig i örat som liten, och för att du är den finaste av storkusiner. För 
att du är klok och gör det du vill. För att du ser och förstår att uppskattar generationer. Lukas 
for president! 
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Linus – för att du gav mig förtroendet att hjälpa dig med postern på högstadiet, även om det 
visade sig vara ett misstag. För ditt och Emelies speciella band när ni var små, för alla skratt 
(tänker just nu på framträdandet med ”Avundsjuk” på midsommarafton) och för att du gör 
ditt eget i alla lägen! 
Mia – för att du orkar med dina svenska kusiner, även efter en lång dag i skidbacken. Jag är 
så glad att du nått ditt första stora mål, det verkade bra mycket tuffare att nå, än att skriva den 
här boken! På tal om bok, ser fram emot att läsa en av dig framöver, i vilket genre det än må 
bli. 
Mormor/far – er saknar jag! Det kommer över mig ibland. Hur glada ni hade varit för min 
skull. Hur varmt det hade varit med en kram. Farmor/far – er minns jag inte så mycket. Men 
jag vet att ni format mig genom det ni gett pappa. Önskar jag hade fått mer tid med er! Alla 
generationer före dess – jag funderar på er ibland. Vilka ni var? Vad ni skickat vidare till 
mig? Varför är vi plötsligt massor av läkare, sjuksköterskor o sjukgymnaster i en generation 
när nästan ingen i generationerna före jobbat inom vården? Vem var det som sådde fröet, som 
fick växa genom generationerna? 
My american family – thank You for not only giving me a home for a year, but a family for 
a lifetime! My first medical research project was the one when I kept agar plates with 
bacteria’s in my closet at your house… It brings me so much happiness to hear my children 
talk about “our Americans”. You are all very special to me! 
 
Melina – min glada, omtänksamma och smarta dotter. Du är orädd, vacker och rolig. Du vill 
och du gör. Du lyssnar och funderar. Du ger kärlek, värme och teckningar. Ditt hjärta är så 
stort, så stort. Min stolthet och glädje. Du kom till slut! Min älskade skatt. Du är den mest 
självklara jag vet. Tänk att just du vill hålla min hand! 
Emelie – min genomkloka, empatiska och vackra dotter. Du är modig och snäll. Du berättar 
om livet, du frågar och du analyserar. Du är en härlig kämpe, fylld med värme! Du skrattar åt 
mina skämt (även när ingen annan gör det) och kramar mig när jag behöver det. Tänk att du 
är min (och har min prick), älskade barn. Men du är tydligt allra mest din egen! Stolt mamma 
är jag. 
Anders – mitt lugn, min hjälp-kompass och mitt mysterium. Ibland min motsats, men alltid 
min trygghet. Du får mig att tänka och skratta, och att bara vara. Du räddar de 30 %, som 
70 % -jag tappar bort. Det vackraste jag vet är att lyssna på samtal mellan dig och barnen. 
Tänk att du fanns ändå! 
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